2024

Osmanska, J., Petrie, M. C. , Docherty, K. F. , Lee, M. M.Y. , McMurray, J. J.V. and Campbell, R. (2024) Subcutaneous furosemide in heart failure: a systematic review. European Heart Journal: Cardiovascular Pharmacotherapy, (doi: 10.1093/ehjcvp/pvae083) (Accepted for Publication)

Averbuch, T., Lee, S. F., Zagorski, B., Pandey, A., Petrie, M. C. , Biering‐Sorensen, T., Xie, F. and Van Spall, H. G.C. (2024) Long‐term clinical outcomes and healthcare resource utilization in male and female patients following hospitalization for heart failure. European Journal of Heart Failure, (doi: 10.1002/ejhf.3499) (PMID:39498574) (Early Online Publication)

Foley, P.W. et al. (2024) Effect of correcting iron deficiency on the risk of serious infection in heart failure insights from the IRONMAN trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3504) (PMID:39453738) (Early Online Publication)

Lee, M. et al. (2024) Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic – insights from the IRONMAN trial. European Journal of Heart Failure, 26(10), pp. 2293-2295. (doi: 10.1002/ejhf.3394) (PMID:39078467)

Sliwa, K. et al. (2024) Living with peripartum cardiomyopathy: A statement from the Heart Failure Association and the Association of Cardiovascular Nursing and Allied Professions of the European Society of Cardiology. European Journal of Heart Failure, 26(10), pp. 2143-2154. (doi: 10.1002/ejhf.3377) (PMID:39115028)

Ryan, M. et al. (2024) Effect of PCI on health status in ischemic left ventricular dysfunction: insights from REVIVED-BCIS2. JACC: Heart Failure, 12(9), pp. 1553-1562. (doi: 10.1016/j.jchf.2024.03.010) (PMID:38727649)

Seferović, P. M. et al. (2024) Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases. European Journal of Heart Failure, 26(9), pp. 1893-1903. (doi: 10.1002/ejhf.3347) (PMID:38896048)

van der Meer, P. et al. (2024) Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry. European Heart Journal, (doi: 10.1093/eurheartj/ehae559) (PMID:39221911) (Accepted for Publication)

Ponikowski, P. et al. (2024) Hospitalization of symptomatic patients with heart failure and moderate to severe functional mitral regurgitation treated with MitraClip: insights from RESHAPE-HF2. JACC: Heart Failure, (doi: 10.1016/j.jacc.2024.08.027) (PMID:39217574) (In Press)

Carberry, J. et al. (2024) Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, 11(4), pp. 2001-2012. (doi: 10.1002/ehf2.14830) (PMID:38715187) (PMCID:PMC11287338)

Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11(4), pp. 1875-1879. (doi: 10.1002/ehf2.14742) (PMID:38549192) (PMCID:PMC11287326)

Gustafsson, F. et al. (2024) 2-year outcomes of an atrial shunt device in HFpEF/HFmrEF: results from REDUCE LAP-HF II. JACC: Heart Failure, 12(8), pp. 1425-1438. (doi: 10.1016/j.jchf.2024.04.011) (PMID:38934964)

Rosano, G. M.C. et al. (2024) Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC. European Journal of Heart Failure, 26(8), pp. 1669-1686. (doi: 10.1002/ejhf.3284) (PMID:38783694)

Zahir Anjum, D. et al. (2024) Use of medical therapy and risk of clinical events according to frailty in heart failure patients – A real‐life cohort study. European Journal of Heart Failure, 26(8), pp. 1717-1726. (doi: 10.1002/ejhf.3249) (PMID:38700461)

Ezad, S. M. et al. (2024) Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy. Journal of the American College of Cardiology, 84(4), pp. 340-350. (doi: 10.1016/j.jacc.2024.04.043) (PMID:38759904) (PMCID:PMC11250908)

Schou, M. et al. (2024) Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction the STEP-HFpEF program. Journal of the American College of Cardiology, 84(3), pp. 247-257. (doi: 10.1016/j.jacc.2024.04.038) (PMID:38913004)

Anker, S. D. et al. (2024) Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials. European Journal of Heart Failure, 26(7), pp. 1608-1615. (doi: 10.1002/ejhf.3286) (PMID:38847420)

Savarese, G. et al. (2024) Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice. European Journal of Heart Failure, 26(6), pp. 1408-1418. (doi: 10.1002/ejhf.3214) (PMID:38515385)

Udell, J. A. et al. (2024) Left ventricular function, congestion, and effect of empagliflozin on heart failure risk after myocardial infarction. Journal of the American College of Cardiology, 83(23), pp. 2233-2246. (doi: 10.1016/j.jacc.2024.03.405) (PMID:38588929)

Rankin, S. et al. (2024) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography. bioRxiv, (doi: 10.1101/2024.05.30.596741)

Curtain, J. P. et al. (2024) Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF. European Journal of Heart Failure, 26(6), pp. 1383-1392. (doi: 10.1002/ejhf.3290) (PMID:38741283)

Hernandez, A. F. et al. (2024) Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial. Circulation, 149(21), pp. 1627-1638. (doi: 10.1161/circulationaha.124.069217) (PMID:38581389) (PMCID:PMC11115458)

Ray, R. et al. (2024) The impact of ferric derisomaltose on cardiovascular and non-cardiovascular events in patients with anemia, iron deficiency and heart failure with reduced ejection fraction. Journal of Cardiac Failure, 30(5), pp. 682-690. (doi: 10.1016/j.cardfail.2023.10.006) (PMID:37926238) (PMCID:PMC11096866)

Butler, J. et al. (2024) Empagliflozin after acute myocardial infarction. New England Journal of Medicine, 390(16), pp. 1455-1466. (doi: 10.1056/NEJMoa2314051) (PMID:38587237)

Butler, J. et al. (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet, 403(10437), pp. 1635-1648. (doi: 10.1016/S0140-6736(24)00469-0) (PMID:38599221)

Kosiborod, M. N. et al. (2024) Semaglutide in patients with obesity-related heart failure and type 2 diabetes. New England Journal of Medicine, 390(15), pp. 1394-1407. (doi: 10.1056/NEJMoa2313917) (PMID:38587233)

Rankin, S., Elyan, B. , Jones, R. , Venugopal, B., Mark, P. B. , Lees, J. S. , Petrie, M. C. and Lang, N. N. (2024) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, 6(2), pp. 267-279. (doi: 10.1016/j.jaccao.2023.12.010) (PMID:38774021) (PMCID:PMC11103039)

Glen, C. et al. (2024) Cardiovascular sequalae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart, 110(9), pp. 650-656. (doi: 10.1136/heartjnl-2023-323437) (PMID:38103912) (PMCID:PMC11041571)

Jackson, A. M. et al. (2024) A novel score to predict left ventricular recovery in peripartum cardiomyopathy derived from the ESC EORP Peripartum Cardiomyopathy Registry. European Heart Journal, 45(16), pp. 1430-1439. (doi: 10.1093/eurheartj/ehad888) (PMID:38282532) (PMCID:PMC11032708)

Osmanska, J., Petrie, M. C. and Campbell, R. T. (2024) Reply: subcutaneous furosemide patch: heart failure decongestion "from the comfort of your home". European Heart Journal: Cardiovascular Pharmacotherapy, 10(3), pp. 261-262. (doi: 10.1093/ehjcvp/pvae015) (PMID:38366161)

Knigge, P. et al. (2024) Temporal trends in the initiation of dialysis among patients with heart failure with or without diabetes: a nationwide study from 2002 to 2016. Journal of the American Heart Association, 13(6), e032539. (doi: 10.1161/JAHA.123.032539) (PMID:38471834) (PMCID:PMC11009989)

Campbell, P., Rutten, F. H., Lee, M. M. Y. , Hawkins, N. M. and Petrie, M. C. (2024) Heart failure with preserved ejection fraction: Everything the clinician needs to know. Lancet, 403(10431), pp. 1083-1092. (doi: 10.1016/S0140-6736(23)02756-3) (PMID:38367642)

Sliwa, K. et al. (2024) Socio-economic factors determine maternal and neonatal outcomes in women with peripartum cardiomyopathy: a study of the ESC EORP PPCM registry. International Journal of Cardiology, 398, 131596. (doi: 10.1016/j.ijcard.2023.131596) (PMID:37979788)

Deo, S. V. et al. (2024) Impact of residential social deprivation on prediction of heart failure in patients with type 2 diabetes: External validation and recalibration of the WATCH-DM score using real world data. Circulation: Cardiovascular Quality and Outcomes, 17(3), pp. 267-276. e010166. (doi: 10.1161/circoutcomes.123.010166) (PMID:38328913)

Mellbin, L. G., Bhatt, D. L., David, J.-P., Ekström, K., Petrie, M. C. , Rasmussen, S. and Vilsbøll, T. (2024) Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials. European Heart Journal, 45(15), pp. 1371-1374. (doi: 10.1093/eurheartj/ehae028) (PMID:38416593) (PMCID:PMC11015952)

Rudd, A. E. et al. (2024) Cardiovascular and noncardiovascular prescribing and mortality after takotsubo comparison with myocardial infarction and general population. JACC: Advances, 3(2), 100797. (doi: 10.1016/j.jacadv.2023.100797)

UK HFpEF Collaborative Group, and , (2024) Rationale and design of the United Kingdom Heart Failure with Preserved Ejection Fraction Registry. Heart, 110(5), pp. 359-365. (doi: 10.1136/heartjnl-2023-323049) (PMID:37827557)

Black, N. et al. (2024) Development and validation of imaging-free myocardial fibrosis prediction models, association with outcomes, and sample size estimation for phase 3 trials. medRxiv, (doi: 10.1101/2024.02.07.24302443)

Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)

Vardeny, O. et al. (2024) Dapagliflozin and mode of death in heart failure with improved ejection fraction: A post hoc analysis of the DELIVER trial. JAMA Cardiology, 9(3), pp. 283-289. (doi: 10.1001/jamacardio.2023.5318) (PMID:38265835) (PMCID:PMC10809142)

Omerovic, E. et al. (2024) Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9-pragmatic research and innovation through multinational experimentation. Trials, 25, 80. (doi: 10.1186/s13063-024-07935-y) (PMID:38263138) (PMCID:PMC10807265)

Petrie, M. C. et al. (2024) Pulmonary congestion and left ventricular dysfunction after myocardial infarction: insights from the PARADISE-MI trial. Circulation, 149(4), pp. 335-38. (doi: 10.1161/CIRCULATIONAHA.123.066163) (PMID:38252738)

Kosiborod, M. N. et al. (2024) Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation, 149(3), pp. 204-216. (doi: 10.1161/circulationaha.123.067505) (PMID:37952180) (PMCID:PMC10782938)

Chivardi, C. et al. (2024) Percutaneous revascularization for ischemic left ventricular dysfunction: Cost-effectiveness analysis of the REVIVED-BCIS2 trial. Circulation: Cardiovascular Quality and Outcomes, 17(1), e010533. (doi: 10.1161/circoutcomes.123.010533) (PMID:37929587) (PMCID:PMC10782932)

Jackson, A. et al. (2024) Outcomes at one year in women with peripartum cardiomyopathy: findings from the ESC EORP PPCM Registry. European Journal of Heart Failure, 26(1), pp. 34-42. (doi: 10.1002/ejhf.3055) (PMID:37823238)

Lee, M. M.Y. , Kondo, T., Campbell, R. T., Petrie, M. C. , Sattar, N. , Solomon, S. D., Vaduganathan, M., Jhund, P. S. and McMurray, J. J.V. (2024) Effects of Renin-Angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomised controlled trials. European Heart Journal: Cardiovascular Pharmacotherapy, 10(1), pp. 68-80. (doi: 10.1093/ehjcvp/pvad067) (PMID:37740450) (PMCID:PMC10766905)

McDowell, K., Adamson, C., Jackson, C., Campbell, R., Welsh, P. , Petrie, M. C. , McMurray, J. J.V. , Jhund, P. and Herring, N. (2024) Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. European Journal of Heart Failure, 26(1), pp. 107-116. (doi: 10.1002/ejhf.3085) (PMID:37937329)

Osmanska, J. et al. (2024) A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. European Heart Journal: Cardiovascular Pharmacotherapy, 10, pp. 35-44. (doi: 10.1093/ehjcvp/pvad073) (PMID:37804170) (PMCID:PMC10766906)

2023

Lee, M. M.Y. , Lean, M. E.J. , Sattar, N. and Petrie, M. C. (2023) Appetite and its regulation: Are there palatable interventions for heart failure? Current Heart Failure Reports, 21, pp. 1-4. (doi: 10.1007/s11897-023-00637-7) (PMID:38133864) (PMCID:PMC10827951)

Jackson, A. M. et al. (2023) A 20-year population study of peripartum cardiomyopathy. European Heart Journal, 44(48), pp. 5128-5141. (doi: 10.1093/eurheartj/ehad626) (PMID:37804234) (PMCID:PMC10733720)

Kosiborod, M. N., Borlaug, B. A. and Petrie, M. C. (2023) Semaglutide and heart failure with preserved ejection fraction and obesity. Reply. New England Journal of Medicine, 389(25), pp. 2398-2399. (doi: 10.1056/NEJMc2312296) (PMID:38118037)

Zahir Anjum, D. et al. (2023) Initiation of medical therapy for heart failure patients according to kidney function: a Danish nationwide study. Clinical Epidemiology, 15, pp. 855-866. (doi: 10.2147/clep.s412787) (PMID:37489222) (PMCID:PMC10363354)

Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

Malik, M. E. et al. (2023) Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longevity, 4(10), e552-e560. (doi: 10.1016/S2666-7568(23)00164-2) (PMID:37734395)

Nadarajah, R. et al. (2023) Prediction models for heart failure in the community: a systematic review and meta‐analysis. European Journal of Heart Failure, 25(10), pp. 1724-1738. (doi: 10.1002/ejhf.2970) (PMID:37403669)

Seckin, M., Johnston, B. , Petrie, M. C. , Stewart, S. and Chan, Y.-K. (2023) Characteristics of symptoms and symptom change across different heart failure subtypes: a sex-stratified analysis. European Journal of Cardiovascular Nursing, 22(7), pp. 690-700. (doi: 10.1093/eurjcn/zvac099) (PMID:36288919)

Perera, D. et al. (2023) Arrhythmia and death following percutaneous revascularization in ischemic left ventricular dysfunction: Prespecified analyses from the REVIVED-BCIS2 trial. Circulation: Heart Failure, 148(11), pp. 862-871. (doi: 10.1161/circulationaha.123.065300) (PMID:37555345) (PMCID:PMC10487377)

Harrington, J. et al. (2023) Baseline characteristics of patients enrolled in the EMPACT‐MI trial. European Journal of Heart Failure, 25(9), pp. 1708-1715. (doi: 10.1002/ejhf.2990) (PMID:37622416)

Borlaug, B. A. et al. (2023) Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nature Medicine, 29(9), pp. 2358-2365. (doi: 10.1038/s41591-023-02526-x) (PMID:37635157) (PMCID:PMC10504076)

Ioannou, A. et al. (2023) Conventional heart failure therapy in cardiac ATTR amyloidosis. European Heart Journal, 44(31), pp. 2893-2907. (doi: 10.1093/eurheartj/ehad347) (PMID:37216684) (PMCID:PMC10424879)

Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)

Docherty, K. F. , Jackson, A. M., Macartney, M., Campbell, R. T., Petrie, M. C. , Pfeffer, M. A., McMurray, J. J.V. and Jhund, P. S. (2023) Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016. European Journal of Heart Failure, 25(8), pp. 1213-1224. (doi: 10.1002/ejhf.2965) (PMID:37401485)

Docherty, K. F. , Lam, C. S.P., Rakisheva, A., Coats, A. J.S., Greenhalgh, T., Metra, M., Petrie, M. C. and Rosano, G. M.C. (2023) Heart failure diagnosis in the general community - who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 25(8), pp. 1185-1198. (doi: 10.1002/ejhf.2946) (PMID:37368511)

Tromp, J., Jackson, A. M., Abdelhamid, M., Fouad, D., Youssef, G., Petrie, M. C. , Bauersachs, J., Sliwa, K. and van der Meer, P. (2023) Thrombo‐embolic events in peripartum cardiomyopathy: results from the ESC EORP PPCM registry. European Journal of Heart Failure, 25(8), pp. 1464-1466. (doi: 10.1002/ejhf.2871) (PMID:37092321)

Araki, T. et al. (2023) Relationship between the volume of cases and in-hospital mortality in patients with cardiogenic shock receiving short-term mechanical circulatory support. American Heart Journal, 261, pp. 109-123. (doi: 10.1016/j.ahj.2023.03.017) (PMID:37031832)

Kondo, T. et al. (2023) Predicting stroke in heart failure and preserved ejection fraction without atrial fibrillation. Circulation: Heart Failure, 16(7), e010377. (doi: 10.1161/CIRCHEARTFAILURE.122.010377) (PMID:37350280)

Curtain, J. P., Lee, M. M.Y. , McMurray, J. J.V. , Gardner, R. S., Petrie, M. C. and Jhund, P. S. (2023) Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. Heart, 109(11), pp. 823-831. (doi: 10.1136/heartjnl-2022-321885) (PMID:36522146) (PMCID:PMC10314022)

Gard, E. K. et al. (2023) Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction. European Journal of Heart Failure, 25(6), pp. 806-814. (doi: 10.1002/ejhf.2805) (PMID:36847073)

Lam, C. S. P., Harding, E., Bains, M., Chin, A., Kanumilli, N., Petrie, M. C. , Pohja-Hutchison, P., Yang, J. and Butler, J. (2023) Identification of urgent gaps in public and policymaker knowledge of heart failure: results of a global survey. BMC Public Health, 23, 1023. (doi: 10.1186/s12889-023-15405-4) (PMID:37254075) (PMCID:PMC10227786)

Dewan, P. et al. (2023) Impact of multimorbidity on mortality in HFrEF : which comorbidities matter most? – an analysis of PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 25(5), pp. 687-697. (doi: 10.1002/ejhf.2856) (PMID:37062869)

Butler, J. et al. (2023) Challenges and opportunities for increasing patient involvement in heart failure self-care programs and self-care in the post–hospital discharge period. Research Involvement and Engagement, 9, 23. (doi: 10.1186/s40900-023-00412-x) (PMID:37046357) (PMCID:PMC10097448)

Bruhn, J. et al. (2023) Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study. European Heart Journal, 44(13), pp. 1124-1132. (doi: 10.1093/eurheartj/ehac797) (PMID:36691953)

Butt, J. H. et al. (2023) Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. European Heart Journal, 44(13), pp. 1136-1153. (doi: 10.1093/eurheartj/ehad083) (PMID:36944496) (PMCID:PMC10111968)

Desai, A. S. and Petrie, M. C. (2023) Centrally adjudicated heart failure outcomes are needed in clinical trials. JACC: Heart Failure, 11(4), pp. 418-421. (doi: 10.1016/j.jchf.2023.01.028) (PMID:37019557)

Dobbin, S. J.H. , Shen, L., Petrie, M. C. , Packer, M., Solomon, S. D., McMurray, J. J.V. , Lang, N. N. and Jhund, P. S. (2023) Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. European Journal of Heart Failure, 25(4), pp. 488-496. (doi: 10.1002/ejhf.2818) (PMID:36919816)

Mooney, L., Jackson, C. E., Adamson, C., McConnachie, A. , Welsh, P. , Myles, R. C. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Lang, N. N. (2023) Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circulation: Heart Failure, 16(4), e010051. (doi: 10.1161/CIRCHEARTFAILURE.122.010051) (PMID:36896709) (PMCID:PMC10101136)

Curtain, J. P. et al. (2023) Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. European Heart Journal, 44(8), pp. 668-677. (doi: 10.1093/eurheartj/ehac801) (PMID:36632831)

Pathak, S., Lai, F. Y., Miksza, J., Petrie, M. C. , Roman, M., Murray, S., Dearling, J., Perera, D. and Murphy, G. J. (2023) Surgical or percutaneous coronary revascularization for heart failure: an in silico model using routinely collected health data to emulate a clinical trial. European Heart Journal, 44(5), pp. 351-364. (doi: 10.1093/eurheartj/ehac670) (PMID:36350978) (PMCID:PMC9890210)

Kondo, T. et al. (2023) Prognosis in patients with cardiogenic shock who received temporary mechanical circulatory support. JACC: Asia, 3(1), pp. 122-134. (doi: 10.1016/j.jacasi.2022.10.004) (PMID:36873766) (PMCID:PMC9982290)

Petrie, M. C. et al. (2023) High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovascular Research, 119(1), pp. 213-220. (doi: 10.1093/cvr/cvab317) (PMID:34875022) (PMCID:PMC10022850)

Perera, D. et al. (2023) Viability and outcomes with revascularization or medical therapy in ischemic ventricular dysfunction: a prespecified secondary analysis of the REVIVED-BCIS2 Trial. JAMA Cardiology, 8(12), pp. 1154-1161. (doi: 10.1001/jamacardio.2023.3803) (PMID:37878295) (PMCID:PMC10600721)

2022

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

Mehran, R. et al. (2022) The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE-MI trial. Circulation, 146(23), pp. 1749-1757. (doi: 10.1161/CIRCULATIONAHA.122.060841) (PMID:36321459)

Gregers, M. C. T., Schou, M., Jensen, M. T., Jensen, J., Petrie, M. C. , Vilsbøll, T., Goetze, J. P., Rossing, P. and Jørgensen, P. G. (2022) Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes. Scandinavian Cardiovascular Journal, 56(1), pp. 256-263. (doi: 10.1080/14017431.2022.2095435) (PMID:35811473)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)

Mark, P. B. , Mangion, K., Rankin, A. J. , Rutherford, E., Lang, N. N. , Petrie, M. C. , Stoumpos, S. and Patel, R. K. (2022) Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. Clinical Kidney Journal, 15(12), pp. 2186-2199. (doi: 10.1093/ckj/sfac146) (PMID:36381379) (PMCID:PMC9664574)

Tromp, J., Bauer, D., Claggett, B. L., Frost, M., Iversen, M. B., Prasad, N., Petrie, M. C. , Larson, M. G., Ezekowitz, J. A. and Solomon, S. D. (2022) A formal validation of a deep learning-based automated workflow for the interpretation of the echocardiogram. Nature Communications, 13, 6776. (doi: 10.1038/s41467-022-34245-1) (PMID:36351912) (PMCID:PMC9646849)

Kondo, T. et al. (2022) Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal, 43(42), pp. 4469-4479. (doi: 10.1093/eurheartj/ehac487) (PMID:36017729) (PMCID:PMC9637422)

Arulmurugananthavadivel, A. et al. (2022) Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark 1997–2017. European Heart Journal: Quality of Care and Clinical Outcomes, 8(7), pp. 750-760. (doi: 10.1093/ehjqcco/qcab073) (PMID:34625809) (PMCID:PMC9603536)

Harrington, J. et al. (2022) Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American Heart Journal, 253, pp. 86-98. (doi: 10.1016/j.ahj.2022.05.010) (PMID:35595091)

Garred, C. H. et al. (2022) Adherence and discontinuation of optimal heart failure therapies according to age: a Danish nationwide study. Journal of the American Heart Association, 11(19), e026187. (doi: 10.1161/JAHA.122.026187) (PMID:36172925) (PMCID:PMC9673698)

Desai, A. S. et al. (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction. JAMA Cardiology, 7(12), pp. 1227-1234. (doi: 10.1001/jamacardio.2022.3736) (PMID:36189985) (PMCID:PMC9531084)

Harrington, J., Petrie, M. C. , Anker, S. D., Bhatt, D. L., Jones, S. W., Udell, J. A., Hernandez, A. F. and Butler, J. (2022) Evaluating the application of chronic heart failure therapies and developing treatments in individuals with recent myocardial infarction. JAMA Cardiology, 7(10), pp. 1067-1075. (doi: 10.1001/jamacardio.2022.2847) (PMID:36044233)

Welsh, P. et al. (2022) Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circulation: Heart Failure, 15(10), pp. 957-967. (doi: 10.1161/CIRCHEARTFAILURE.121.009427) (PMID:36098049) (PMCID:PMC9561238)

Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)

Hoes, M. F., Arany, Z., Bauersachs, J., Hilfiker-Kleiner, D., Petrie, M. C. , Sliwa, K. and van der Meer, P. (2022) Pathophysiology and risk factors of peripartum cardiomyopathy. Nature Reviews Cardiology, 19(8), pp. 555-565. (doi: 10.1038/s41569-021-00664-8) (PMID:35017720)

Ryan, M., Perera, D. and Petrie, M. C. (2022) Revascularisation and HFpEF – time for randomised trials. European Journal of Heart Failure, 24(8), pp. 1439-1440. (doi: 10.1002/ejhf.2583) (PMID:35729798)

Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)

Shen, L. et al. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)

Curtain, J. P. et al. (2022) Clinical outcomes related to background diuretic use and new diuretic initiation in patients with HFrEF. JACC: Heart Failure, 10(6), pp. 415-427. (doi: 10.1016/j.jchf.2022.01.020) (PMID:35654526)

Jackson, A. M., Benson, L., Savarese, G., Hage, C., Jhund, P. S. , Petrie, M. C. , Dahlström, U., McMurray, J. J.V. and Lund, L. H. (2022) Apparent treatment-resistant hypertension across the spectrum of heart failure phenotypes in the Swedish HF Registry. JACC: Heart Failure, 10(6), pp. 380-392. (doi: 10.1016/j.jchf.2022.04.006) (PMID:35654522)

Borlaug, B. A. et al. (2022) Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure. Circulation, 145(21), pp. 1592-1604. (doi: 10.1161/CIRCULATIONAHA.122.059486) (PMID:35354306) (PMCID:PMC9133195)

Udell, J. A., Jones, W. S., Petrie, M. C. , Harrington, J., Anker, S. D., Bhatt, D. L., Hernandez, A. F. and Butler, J. (2022) Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC Review Topic of the Week. Journal of the American College of Cardiology, 79(20), pp. 2058-2068. (doi: 10.1016/j.jacc.2022.03.353) (PMID:35589167) (PMCID:PMC8972442)

Cohen, D. J. et al. (2022) Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation. Heart, 108(9), pp. 717-724. (doi: 10.1136/heartjnl-2021-320005) (PMID:35078867) (PMCID:PMC8995818)

He, W. et al. (2022) Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size. Cardiovascular Research, 118(6), pp. 1535-1547. (doi: 10.1093/cvr/cvab204) (PMID:34132807)

Yeoh, S. E. et al. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)

Cotton, S. et al. (2022) Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 23, 307. (doi: 10.1186/s13063-022-06226-8) (PMID:35422024) (PMCID:PMC9009490)

Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)

Curtain, J. P. et al. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J. , Jones, R. J. , Petrie, M. C. and Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4(1), pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096) (PMID:35492830) (PMCID:PMC9040125)

Jackson, A. M. et al. (2022) Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 24(3), pp. 497-509. (doi: 10.1002/ejhf.2403) (PMID:34918855) (PMCID:PMC9542636)

Lee, M. M.Y. et al. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)

Deis, T. et al. (2022) Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction. ESC Heart Failure, 9(1), pp. 186-195. (doi: 10.1002/ehf2.13697) (PMID:34877822) (PMCID:PMC8788022)

Docherty, K. F. and Petrie, M. C. (2022) Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 108(4), pp. 312-320. (doi: 10.1136/heartjnl-2020-318658) (PMID:34127540)

Januzzi, J. L. et al. (2022) Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. Journal of Hematology and Oncology, 15(1), 1. (doi: 10.1186/s13045-021-01221-z) (PMID:34991679) (PMCID:PMC8734305)

Pfeffer, M. A. et al. (2022) Impact of sacubitril/valsartan versus ramipril on total heart failure events in the PARADISE-MI trial. Circulation, 145(1), pp. 87-89. (doi: 10.1161/CIRCULATIONAHA.121.057429) (PMID:34797725)

Chan, Y., Seckin, M., Johnston, B., Petrie, M. and Stewart, S. (2022) Characteristics of symptom change in men and women with different heart failure subtypes. Heart, Lung and Circulation, 31(Suppl3), S76. (doi: 10.1016/j.hlc.2022.06.074)

2021

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Diamant, M. J., Andrade, J. G., Virani, S. A., Jhund, P. S. , Petrie, M. C. and Hawkins, N. M. (2021) Heart failure and atrial flutter: a systematic review of current knowledge and practices. ESC Heart Failure, 8(6), pp. 4484-4496. (doi: 10.1002/ehf2.13526) (PMID:34505352) (PMCID:PMC8712920)

Jackson, A. M. et al. (2021) Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. European Journal of Heart Failure, 23(12), pp. 2058-2069. (doi: 10.1002/ejhf.2264) (PMID:34114268)

Mark, P. B. et al. (2021) Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. Kidney360, 2(11), pp. 1761-1769. (doi: 10.34067/KID.0004272021)

Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)

Rush, C. J. et al. (2021) Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiology, 6(10), pp. 1130-1143. (doi: 10.1001/jamacardio.2021.1825) (PMID:34160566) (PMCID:PMC8223134)

Curtain, J. P. et al. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)

Rørth, R. et al. (2021) Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. PLoS ONE, 16(8), e0255364. (doi: 10.1371/journal.pone.0255364) (PMID:34347805) (PMCID:PMC8336831)

Graham, F. J., Pellicori, P. , Ford, I. , Petrie, M. C. , Kalra, P. R. and Cleland, J. G.F. (2021) Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clinical Research in Cardiology, 110(8), pp. 1299-1307. (doi: 10.1007/s00392-021-01837-8) (PMID:33755777)

Petrie, M. C. , Lee, M. M.Y. and Docherty, K. F. (2021) Sodium–glucose co-transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction? European Journal of Heart Failure, 23(8), pp. 1256-1259. (doi: 10.1002/ejhf.2108) (PMID:33502794)

Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)

Lee, M. M.Y. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Sattar, N. (2021) Response by Lee et al to letter regarding article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". Circulation, 144(3), e40. (doi: 10.1161/CIRCULATIONAHA.121.055067) (PMID:34279995)

Jhund, P. S. et al. (2021) Heart failure hospitalization in adults receiving maintenance hemodialysis and effect of intravenous iron therapy: A report from PIVOTAL. JACC: Heart Failure, 9(7), pp. 518-527. (doi: 10.1016/j.jchf.2021.04.005) (PMID:34119470)

Simpson, J. et al. (2021) Adherence to prescribed medications in patients with heart failure – insights from liquid chromatography-tandem mass spectrometry-based urine analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 7(4), pp. 296-301. (doi: 10.1093/ehjcvp/pvaa071) (PMID:32597982) (PMCID:PMC8302254)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)

Maznyczka, A. M. et al. (2021) Thermodilution-derived temperature recovery time, a novel predictor of microvascular reperfusion and prognosis after myocardial infarction. EuroIntervention, 17(3), pp. 220-228. (doi: 10.4244/EIJ-D-19-00904) (PMID:32122822)

Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)

Rossitto, G. et al. (2021) High sodium intake, glomerular hyperfiltration and protein catabolism in patients with essential hypertension. Cardiovascular Research, 117(5), pp. 1372-1381. (doi: 10.1093/cvr/cvaa205) (PMID:33053160) (PMCID:PMC8064429)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)

Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)

Mbakwem, A. C. et al. (2021) Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy: results from the ESC EORP PPCM registry. ESC Heart Failure, 8(2), pp. 879-889. (doi: 10.1002/ehf2.13172) (PMID:33453082) (PMCID:PMC8006717)

Mooney, L., Goodyear, C. S. , Chandra, T., Kirschner, K. , Copland, M. , Petrie, M. C. and Lang, N. N. (2021) Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. Clinical Science, 135(7), pp. 991-1007. (doi: 10.1042/CS20200306) (PMID:33861346) (PMCID:PMC8055963)

Sliwa, K. et al. (2021) Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 23(4), pp. 527-540. (doi: 10.1002/ejhf.2133) (PMID:33609068)

Tomasoni, D., Petrie, M. C. , Adamo, M. and Metra, M. (2021) Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy. European Journal of Heart Failure, 23(3), pp. 486-488. (doi: 10.1002/ejhf.2098) (PMID:33421242) (PMCID:PMC8013611)

Lee, M. M.Y. et al. (2021) Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. Open Heart, 8(1), e001453. (doi: 10.1136/openhrt-2020-001453) (PMID:33637568) (PMCID:PMC7919592)

Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

Petrie, M. C. , Lee, M. M. and Lang, N. N. (2021) EMPEROR-REDUCED reigns while EMPERIAL whimpers. European Heart Journal, 42(6), pp. 711-714. (doi: 10.1093/eurheartj/ehaa965) (PMID:33367572)

Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)

Maznyczka, A. M. et al. (2021) Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. Heart, 107(4), pp. 299-312. (doi: 10.1136/heartjnl-2020-317828) (PMID:33436493)

Dobbin, S. J.H. , Petrie, M. C. , Myles, R. C. , Touyz, R. M. and Lang, N. N. (2021) Cardiotoxic effects of angiogenesis inhibitors. Clinical Science, 135(1), pp. 71-100. (doi: 10.1042/CS20200305) (PMID:33404052) (PMCID:PMC7812690)

2020

Rossitto, G. et al. (2020) Reduced lymphatic reserve in heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 76(24), pp. 2817-2829. (doi: 10.1016/j.jacc.2020.10.022) (PMID:33303070) (PMCID:PMC7724570)

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Mackenzie, I. S. et al. (2020) Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, 396(10264), pp. 1745-1757. (doi: 10.1016/S0140-6736(20)32234-0) (PMID:33181081)

Dewan, P. et al. (2020) The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 22(11), pp. 2123-2133. (doi: 10.1002/ejhf.1832) (PMID:32353205)

Ferreira, J. P. et al. (2020) Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 109(11), pp. 1358-1365. (doi: 10.1007/s00392-020-01632-x) (PMID:32215700)

McCartney, P. J. et al. (2020) Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. Efficacy and Mechanism Evaluation, 7(5), (doi: 10.3310/eme07050) (PMID:33175484)

McEwan, P., Darlington, O., McMurray, J. J.V. , Jhund, P. S. , Docherty, K. F. , Böhm, M., Petrie, M. C. , Bergenheim, K. and Qin, L. (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22(11), pp. 2147-2156. (doi: 10.1002/ejhf.1978) (PMID:32749733) (PMCID:PMC7756637)

Seferović, P. M. et al. (2020) Heart Failure Association of the European Society of Cardiology update on sodium glucose co‐transporter‐2 inhibitors in heart failure (an update on the Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology). European Journal of Heart Failure, 22(11), pp. 1984-1986. (doi: 10.1002/ejhf.2026) (PMID:33068051)

Lang, N. N. , Dobbin, S. J.H. and Petrie, M. C. (2020) Vericiguat in worsening heart failure – agonising over, or celebrating, agonism. Cardiovascular Research, 116(12), e152-e155. (doi: 10.1093/cvr/cvaa247) (PMID:32980877)

Butt, J. H. et al. (2020) Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. European Journal of Heart Failure, 22(10), pp. 1777-1785. (doi: 10.1002/ejhf.1800) (PMID:32227556)

Seferović, P. M. et al. (2020) Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 22(9), pp. 1495-1503. (doi: 10.1002/ejhf.1954) (PMID:32618086)

Rossitto, G. et al. (2020) Tissue sodium excess is not hypertonic and reflects extracellular volume expansion. Nature Communications, 11, 4222. (doi: 10.1038/s41467-020-17820-2) (PMID:32839436) (PMCID:PMC7445299)

Bulluck, H. et al. (2020) Redefining adverse and reverse left ventricular remodeling by cardiovascular magnetic resonance following ST-segment elevation myocardial infarction and their implications on long-term prognosis. Circulation: Cardiovascular Imaging, 13(7), e009937. (doi: 10.1161/CIRCIMAGING.119.009937) (PMID:32689822)

Dobbin, S. J.H. et al. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22(7), pp. 1276-1277. (doi: 10.1002/ejhf.1847) (PMID:32379945)

Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)

Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)

Hawkins, N. M., Osmanska, J. and Petrie, M. C. (2020) Implantable cardioverter-defibrillators and survival - the fine line between efficacy concerns and ageism. European Journal of Heart Failure, 22(5), pp. 868-870. (doi: 10.1002/ejhf.1803) (PMID:32227573)

Hennigan, B. et al. (2020) Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial. Heart, 106(10), pp. 714-715. (doi: 10.1136/heartjnl-2019-316075) (PMID:32114516) (PMCID:PMC7229900)

Maznyczka, A. M. et al. (2020) Comparative significance of invasive measures of microvascular injury in acute myocardial infarction. Circulation: Cardiovascular Interventions, 13(5), e008505. (doi: 10.1161/CIRCINTERVENTIONS.119.008505) (PMID:32408817) (PMCID:PMC7237023)

Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)

Simpson, J. et al. (2020) Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish Heart Failure Registry to predict mortality and morbidity in chronic heart failure. JAMA Cardiology, 5(4), pp. 432-441. (doi: 10.1001/jamacardio.2019.5850) (PMID:31995119)

Docherty, K. F. et al. (2020) Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22(3), pp. 528-538. (doi: 10.1002/ejhf.1682) (PMID:31849164)

Lee, M. M.Y. , Petrie, M. C. , McMurray, J. J.V. and Sattar, N. (2020) How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? Arteriosclerosis, Thrombosis, and Vascular Biology, 40(3), pp. 506-522. (doi: 10.1161/atvbaha.119.311904) (PMID:31996025)

Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)

Ford, T. J. et al. (2020) Sex differences in procedural and clinical outcomes following rotational atherectomy. Catheterization and Cardiovascular Interventions, 95(2), pp. 232-241. (doi: 10.1002/ccd.28373) (PMID:31264314) (PMCID:PMC7027486)

Maznyczka, A. M. et al. (2020) One-year outcomes after low-dose intracoronary alteplase during primary percutaneous coronary intervention. The T-TIME randomized trial. Circulation: Cardiovascular Interventions, 13(2), e008855. (doi: 10.1161/CIRCINTERVENTIONS.119.008855) (PMID:32069113)

Seferović, P. M. et al. (2020) European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure. European Journal of Heart Failure, 22(2), pp. 196-213. (doi: 10.1002/ejhf.1673) (PMID:31816162)

Kosiborod, M. N. et al. (2020) Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138) (PMID:31736335) (PMCID:PMC6964869)

Martinez, F. A. et al. (2020) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation, 141(2), pp. 100-111. (doi: 10.1161/CIRCULATIONAHA.119.044133) (PMID:31736328)

Heggie, R., Wu, O. , Boyd, K. , Lee, M. M.Y., Petrie, M. C. , McEntegart, M. and Berry, C. (2020) Does routine invasive management benefit patients presenting with an acute coronary syndrome and a history of bypass surgery? The use of clinical outcomes compared with cost-effectiveness outcomes. EUHEA 2020, Oslo, Norway, 7-10 July 2020 [Event cancelled].

2019

Dewan, P. et al. (2019) Sex-related differences in heart failure with preserved ejection fraction. Circulation: Heart Failure, 12(12), e006539. (doi: 10.1161/CIRCHEARTFAILURE.119.006539) (PMID:31813280)

McMurray, J. J.V. et al. (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)

Stirrat, C. G. et al. (2019) Ferumoxytol-enhanced MRI in patients with prior cardiac transplantation. Open Heart, 6(2), e001115. (doi: 10.1136/openhrt-2019-001115) (PMID:31673393) (PMCID:PMC6802993)

Anker, S. D. et al. (2019) Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial. European Journal of Heart Failure, 21(10), pp. 1279-1287. (doi: 10.1002/ejhf.1596) (PMID:31523904)

Howlett, J. G. et al. (2019) CABG improves outcomes in patients with ischemic cardiomyopathy 10-year follow-up of the STICH trial. JACC: Heart Failure, 7(10), pp. 878-887. (doi: 10.1016/j.jchf.2019.04.018) (PMID:31521682)

Packer, M. et al. (2019) Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial. European Journal of Heart Failure, 21(10), pp. 1270-1278. (doi: 10.1002/ejhf.1536) (PMID:31584231)

Nicolau, J. C. et al. (2019) Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. International Journal of Cardiology, 291, pp. 36-41. (doi: 10.1016/j.ijcard.2019.03.029) (PMID:30929973)

Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)

Lee, M. M.Y. et al. (2019) Invasive versus medical management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: a pilot randomized controlled trial. Circulation: Cardiovascular Interventions, 12(8), e007830. (doi: 10.1161/CIRCINTERVENTIONS.119.007830) (PMID:31362541)

Rørth, R., Dewan, P. , Kristensen, S. L., Jhund, P. S. , Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2019) Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clinical Research in Cardiology, 108(8), pp. 868-877. (doi: 10.1007/s00392-019-01415-z) (PMID:30689020) (PMCID:PMC6652172)

Shen, L. et al. (2019) Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 21(8), pp. 974-984. (doi: 10.1002/ejhf.1535) (PMID:31271255) (PMCID:PMC7079555)

Bauersachs, J. et al. (2019) Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 21(7), pp. 827-843. (doi: 10.1002/ejhf.1493) (PMID:31243866)

Cleland, J. G.F. , Hindricks, G. and Petrie, M. (2019) The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization. European Heart Journal, 40(26), pp. 2128-2130. (doi: 10.1093/eurheartj/ehz409) (PMID:31257403)

Ahmad, F. A., Petrie, M. C. , McMurray, J. J.V. and Lang, N. N. (2019) Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. European Journal of Heart Failure, 21(6), pp. 699-702. (doi: 10.1002/ejhf.1463) (PMID:30972879) (PMCID:PMC6618029)

Clark, A. L., Kalra, P. R., Petrie, M. C. , Mark, P. B. , Tomlinson, L. A. and Tomson, C. R.V. (2019) Change in renal function associated with drug treatment in heart failure: national guidance. Heart, 105(12), pp. 904-910. (doi: 10.1136/heartjnl-2018-314158) (PMID:31118203) (PMCID:PMC6582720)

Haig, C. et al. (2019) Current smoking and prognosis after acute ST-segment elevation myocardial infarction: new pathophysiological insights. JACC: Cardiovascular Imaging, 12(6), pp. 993-1003. (doi: 10.1016/j.jcmg.2018.05.022) (PMID:30031700) (PMCID:PMC6547246)

Dewan, P. et al. (2019) Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 21(5), pp. 577-587. (doi: 10.1002/ejhf.1347) (PMID:30536678) (PMCID:PMC6607486)

McMurray, J. J.V. et al. (2019) A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). European Journal of Heart Failure, 21(5), pp. 665-675. (doi: 10.1002/ejhf.1432) (PMID:30895697) (PMCID:PMC6607736)

Shen, L. et al. (2019) Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7(5), pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006) (PMID:30981744)

Maznyczka, A. M. et al. (2019) Sex-based associations with microvascular injury and outcomes after ST-segment elevation myocardial infarction. Open Heart, 6(1), e000979. (doi: 10.1136/openhrt-2018-000979) (PMID:31168381) (PMCID:PMC6519583)

Pettit, S. J. and Petrie, M. C. (2019) Transplantation of hearts donated after circulatory-determined death: a song of fire and ice. Circulation: Heart Failure, 12(4), e005991. (doi: 10.1161/CIRCHEARTFAILURE.119.005991) (PMID:30998399)

Wolsk, E. et al. (2019) Central and peripheral determinants of exercise capacity in heart failure patients with preserved ejection fraction. JACC: Heart Failure, 7(4), pp. 321-332. (doi: 10.1016/j.jchf.2019.01.006) (PMID:30852235)

Januzzi, J. et al. (2019) Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 21(3), pp. 386-388. (doi: 10.1002/ejhf.1419) (PMID:30767353)

Loader, J. et al. (2019) Prevalence and profile of "seasonal frequent flyers" with chronic heart disease: analysis of 1598 patients and 4588 patient-years follow-up. International Journal of Cardiology, 279, pp. 126-132. (doi: 10.1016/j.ijcard.2018.12.060) (PMID:30638747)

Mamet, H., Petrie, M. C. and Rocchiccioli, P. (2019) Type 1 diabetes mellitus and coronary revascularization. Cardiovascular Endocrinology and Metabolism, 8(1), pp. 35-38. (doi: 10.1097/XCE.0000000000000166) (PMID:31646296) (PMCID:PMC6739890)

Mangion, K. et al. (2019) Predictors of segmental myocardial functional recovery in patients after an acute ST-elevation myocardial infarction. European Journal of Radiology, 112, pp. 121-129. (doi: 10.1016/j.ejrad.2019.01.010) (PMID:30777200) (PMCID:PMC6390173)

Avtaar Singh, S. S. et al. (2019) Mechanical circulatory support for refractory cardiogenic shock post-acute myocardial infarction-a decade of lessons. Journal of Thoracic Disease, 11(2), pp. 542-548. (doi: 10.21037/jtd.2019.01.21) (PMID:30962998) (PMCID:PMC6409252)

Kaye, D. M. et al. (2019) Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Failure, 6(1), pp. 62-69. (doi: 10.1002/ehf2.12350) (PMID:30311437) (PMCID:PMC6351895)

Mangion, K. et al. (2019) Circumferential strain predicts major adverse cardiovascular events following an acute ST-segment-elevation myocardial infarction. Radiology, 290(2), pp. 329-337. (doi: 10.1148/radiol.2018181253) (PMID:30457480)

Lee, M. M.Y. , Campbell, R. T., Kelly, R., Petrie, M. C. and Sonecki, P. (2019) Does “Scar” at Rest Echocardiography Predict Lack of Contractility Reserve at Dobutamine Stress Echocardiography. EuroEcho-Imaging 2018 Poster Session, Milan, Italy, Dec 2018. (doi: 10.1093/ehjci/jey266)

Dewan, P. et al. (2019) Differential impact of heart failure with reduced ejection fraction on men and women. Journal of the American College of Cardiology, 73(1), pp. 29-40. (doi: 10.1016/j.jacc.2018.09.081) (PMID:30621948)

McCartney, P. J. et al. (2019) Effect of low-dose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction: a randomized clinical trial. JAMA: Journal of the American Medical Association, 321(1), pp. 56-68. (doi: 10.1001/jama.2018.19802) (PMID:30620371) (PMCID:PMC6583564)

Lee, M. M. Y. , McMurray, J. J.V. , Lorenzo-Almorós, A., Kristensen, S. L., Sattar, N. , Jhund, P. S. and Petrie, M. C. (2019) Diabetic cardiomyopathy. Heart, 105(4), pp. 337-345. (doi: 10.1136/heartjnl-2016-310342) (PMID:30337334)

Rush, C. J. and Petrie, M. C. (2019) Heart failure with preserved ejection fraction. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 397-408. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_37)

2018

Campbell, R. T., Petrie, M. C. and McMurray, J. J.V. (2018) Redefining heart failure phenotypes based on ejection fraction. European Journal of Heart Failure, 20(12), pp. 1634-1635. (doi: 10.1002/ejhf.1325) (PMID:30328651)

Campbell, R. T., Petrie, M. C. and McMurray, J. J.V. (2018) Talking to patients with heart failure about end of life. European Journal of Heart Failure, 20(12), pp. 1763-1765. (doi: 10.1002/ejhf.1321) (PMID:30295978) (PMCID:PMC6607510)

Dobbin, S. J.H. , Cameron, A. C., Petrie, M. C. , Jones, R. J. , Touyz, R. M. and Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104(24), pp. 1995-2002. (doi: 10.1136/heartjnl-2018-313726) (PMID:30228246) (PMCID:PMC6268130)

Rossitto, G., Touyz, R. M. , Petrie, M. C. and Delles, C. (2018) Much Ado about N...atrium: modelling tissuesodium as a highly sensitive marker of subclinicaland localized oedema. Clinical Science, 132(24), pp. 2609-2613. (doi: 10.1042/CS20180575) (PMID:30545897) (PMCID:PMC6365627)

Kristensen, S. L., Rørth, R., Jhund, P. S. , Shen, L., Lee, M. M.Y. , Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2018) Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial. European Journal of Heart Failure, 20(11), pp. 1549-1556. (doi: 10.1002/ejhf.1201) (PMID:29727039)

Rush, C. J., Campbell, R. T., Jhund, P. S. , Petrie, M. C. and McMurray, J. J.V. (2018) Association is not causation: treatment effects cannot be estimated from observational data in heart failure. European Heart Journal, 39(37), pp. 3417-3438. (doi: 10.1093/eurheartj/ehy407) (PMID:30085087) (PMCID:PMC6166137)

Shah, S. J. et al. (2018) One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: a randomized clinical trial. JAMA Cardiology, 3(10), pp. 968-977. (doi: 10.1001/jamacardio.2018.2936) (PMID:30167646) (PMCID:PMC6233816)

Campbell, R. T. et al. (2018) Which patients with heart failure should receive specialist palliative care? European Journal of Heart Failure, 20(9), pp. 1338-1347. (doi: 10.1002/ejhf.1240) (PMID:29952090) (PMCID:PMC6607479)

Carberry, J. et al. (2018) Persistent iron within the infarct core after ST-segment elevation myocardial infarction: implications for left ventricular remodeling and health outcomes. JACC: Cardiovascular Imaging, 11(9), pp. 1248-1256. (doi: 10.1016/j.jcmg.2017.08.027) (PMID:29153575) (PMCID:PMC6130225)

Carrick, D. et al. (2018) Hypertension, microvascular pathology and prognosis after an acute myocardial infarction. Hypertension, 72(3), pp. 720-730. (doi: 10.1161/HYPERTENSIONAHA.117.10786) (PMID:30012869) (PMCID:PMC6080885)

McDowell, K., Petrie, M. C. , Raihan, N. A. and Logue, J. (2018) Effects of intentional weight loss in patients with obesity and heart failure: a systematic review. Obesity Reviews, 19(9), pp. 1189-1204. (doi: 10.1111/obr.12707) (PMID:30051959)

McEntegart, M. B. et al. (2018) Incidence of procedural myocardial infarction and cardiac magnetic resonance imaging-detected myocardial injury following percutaneous coronary intervention with rotational atherectomy. EuroIntervention, 14(7), pp. 819-823. (doi: 10.4244/EIJ-D-17-01077) (PMID:29741483)

Wessler, J. et al. (2018) Impact of baseline hemodynamics on the effects of a transcatheter interatrial shunt device in heart failure with preserved ejection fraction. Circulation: Heart Failure, 11(8), e004540. (doi: 10.1161/CIRCHEARTFAILURE.117.004540)

Yew, S. N. et al. (2018) Coronary thermodilution waveforms after acute reperfused ST‐segment–elevation myocardial infarction: relation to microvascular obstruction and prognosis. Journal of the American Heart Association, 7(15), e008957. (doi: 10.1161/JAHA.118.008957) (PMID:30371237) (PMCID:PMC6201480)

Rørth, R., Jhund, P. S. , Mogensen, U. M., Kristensen, S. L., Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2018) Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction. Diabetes Care, 41(6), pp. 1285-1291. (doi: 10.2337/dc17-2583) (PMID:29626073)

Perera, D. et al. (2018) Percutaneous revascularization for ischemic ventricular dysfunction: rationale and design of the REVIVED-BCIS2 trial: percutaneous coronary intervention for ischemic cardiomyopathy. JACC: Heart Failure, 6(6), pp. 517-526. (doi: 10.1016/j.jchf.2018.01.024) (PMID:29852933)

Sliwa, K., Petrie, M. C. , Hilfiker-Kleiner, D., Mebazaa, A., Jackson, A., Johnson, M. R., van der Meer, P., Mbakwem, A. and Bauersachs, J. (2018) Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 20(6), pp. 951-962. (doi: 10.1002/ejhf.1178) (PMID:29578284)

Jackson, A. M., Dalzell, J. R., Walker, N. L., Coats, C. J. , Jhund, P. S. and Petrie, M. C. (2018) Peripartum cardiomyopathy: diagnosis and management. Heart, 104(9), pp. 779-786. (doi: 10.1136/heartjnl-2016-310599) (PMID:29122930)

Seferović, P. M. et al. (2018) Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 20(5), pp. 853-872. (doi: 10.1002/ejhf.1170) (PMID:29520964)

Petrie, M. C. and Rocchiccioli, P. (2018) Coronary angiography in heart failure: when and why? Uncertainty reigns. Heart, 104(7), pp. 548-549. (doi: 10.1136/heartjnl-2017-312200)

Lee, M. M.Y. et al. (2018) Non-Invasive Versus Invasive Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome: Comparisons Between the Randomized Controlled Pilot Trial and Registry. ACC.18, Orlando, FL, USA, 10-12 Mar 2018. A45. (doi: 10.1016/S0735-1097(18)30586-2)

Petrie, M. C. , Connelly, D. T. and Gardner, R. S. (2018) Who needs an implantable cardioverter-defibrillator? Controversies and opportunities after DANISH. European Journal of Heart Failure, 20(3), pp. 413-416. (doi: 10.1002/ejhf.1135) (PMID:29327793)

Stewart, R. A.H. et al. (2018) Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. Open Heart, 5(1), e000752. (doi: 10.1136/openhrt-2017-000752) (PMID:29531766) (PMCID:PMC5845417)

Velazquez, E. J. and Petrie, M. C. (2018) CABG or PCI for diabetic patients with left ventricular dysfunction: closing in on the truth? Journal of the American College of Cardiology, 71(8), pp. 828-831. (doi: 10.1016/j.jacc.2018.01.014) (PMID:29471932)

Rørth, R. et al. (2018) Employment status at time of first hospitalization for heart failure is associated with death and rehospitalization for heart failure. European Journal of Heart Failure, 20(2), pp. 240-247. (doi: 10.1002/ejhf.1046) (PMID:29148231)

Feldman, T. et al. (2018) Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A phase 2, randomized, sham-controlled trial. Circulation, 137(4), pp. 364-375. (doi: 10.1161/CIRCULATIONAHA.117.032094) (PMID:29142012)

Lee, M. M.Y. et al. (2018) Routine Non-invasive vs Invasive Management in Patients With Prior CABG With a NSTE-ACS: a Randomised Controlled Trial. British Cardiovascular Intervention Society Young Investigator Award Shortlisted Presentations, London, UK, 30 Nov 2017. A5.2-A6. (doi: 10.1136/heartjnl-2018-BCIS.9)

Rørth, R. et al. (2018) Evidence based therapy and its association with workforce detachment following first hospitalization for heart failure. JACC: Heart Failure, 6(1), pp. 41-48. (doi: 10.1016/j.jchf.2017.09.019) (PMID:29226811)

Bouabdallaoui, N. et al. (2018) Society of Thoracic Surgeons risk score and EuroSCORE-2 appropriately assess 30-day postoperative mortality in the STICH trial and a contemporary cohort of patients with left ventricular dysfunction undergoing surgical revascularization. Circulation: Heart Failure, 11(11), e005531. (doi: 10.1161/circheartfailure.118.005531) (PMID:30571194) (PMCID:PMC6309904)

Rørth, R. et al. (2018) Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure: a nationwide cohort study. Clinical Epidemiology, 10, pp. 917-930. (doi: 10.2147/CLEP.S164795) (PMID:30123004) (PMCID:PMC6080879)

2017

Carberry, J. et al. (2017) Persistence of infarct zone T2 hyperintensity at 6 months after acute ST-elevation myocardial infarction: incidence, pathophysiology and prognostic implications. Circulation: Cardiovascular Imaging, 10(12), e006586. (doi: 10.1161/CIRCIMAGING.117.006586) (PMID:29242240) (PMCID:PMC5753833)

Hilfiker-Kleiner, D. et al. (2017) Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. European Journal of Heart Failure, 19(12), pp. 1723-1728. (doi: 10.1002/ejhf.808) (PMID:28345302)

Holman, R. R. et al. (2017) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology, 5(11), pp. 877-886. (doi: 10.1016/S2213-8587(17)30309-1) (PMID:28917545)

Wong, C. M. et al. (2017) Heart failure in young adults is associated with high mortality: a contemporary population-level analysis. Canadian Journal of Cardiology, 33(11), pp. 1472-1477. (doi: 10.1016/j.cjca.2017.05.009) (PMID:28941947)

Sliwa, K. et al. (2017) Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM). European Journal of Heart Failure, 19(9), pp. 1131-1141. (doi: 10.1002/ejhf.780) (PMID:28271625)

Shen, L. et al. (2017) Declining risk of sudden death in heart failure. New England Journal of Medicine, 377(1), pp. 41-51. (doi: 10.1056/NEJMoa1609758) (PMID:28679089)

Cleland, J. G.F. , Pellicori, P. , Clark, A. L. and Petrie, M. C. (2017) Time to take the failure out of heart failure: the importance of optimism. JACC: Heart Failure, 5(7), pp. 538-540. (doi: 10.1016/j.jchf.2017.04.003) (PMID:28624485)

Sattar, N. , Petrie, M. C. , Zinman, B. and Januzzi Jr., J. L. (2017) Novel diabetes drugs and the cardiovascular specialist. Journal of the American College of Cardiology, 69(21), pp. 2646-2656. (doi: 10.1016/j.jacc.2017.04.014) (PMID:28545639)

Packer, M. et al. (2017) Effect of ularitide on cardiovascular mortality in acute heart failure. New England Journal of Medicine, 376(20), pp. 1956-1964. (doi: 10.1056/NEJMoa1601895) (PMID:28402745)

Packer, M. et al. (2017) Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure : primary results of the ENABLE Trials. JACC: Heart Failure, 5(5), pp. 317-326. (doi: 10.1016/j.jchf.2017.02.021) (PMID:28449795)

Layland, J. J. et al. (2017) Decision Making Using Fractional Flow Reserve is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With NSTEMI. American College of Cardiology 66th Annual Scientific Session (ACC.17), Washington, D.C., USA, 17-19 Mar 2017. p. 1057. (doi: 10.1016/s0735-1097(17)34446-7)

Docherty, K. F. , Campbell, R. T., Jhund, P. , Petrie, M. C. and McMurray, J. J.V. (2017) How robust are clinical trials in heart failure? European Heart Journal, 38(5), pp. 338-345. (doi: 10.1093/eurheartj/ehw427) (PMID:27742808)

Kristensen, S. L. et al. (2017) Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction. A report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-Preserve). Circulation, 135(8), pp. 724-735. (doi: 10.1161/CIRCULATIONAHA.116.024593) (PMID:28052977)

2016

Carrick, D. et al. (2016) Comparative prognostic utility of indexes of microvascular function alone or in combination in patients with an acute ST-segment elevation myocardial infarction. Circulation, 134(23), pp. 1833-1847. (doi: 10.1161/CIRCULATIONAHA.116.022603) (PMID:27803036) (PMCID:PMC5131697)

Kaye, D. M. et al. (2016) One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circulation: Heart Failure, 9(12), e003662. (doi: 10.1161/CIRCHEARTFAILURE.116.003662) (PMID:27852653) (PMCID:PMC5175994)

Petrie, M. C. et al. (2016) Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation, 134(18), pp. 1314-1324. (doi: 10.1161/CIRCULATIONAHA.116.024800) (PMID:27573034)

Hennigan, B. et al. (2016) Discordance between resting and hyperemic indices of coronary stenosis severity: the VERIFY 2 study (a comparative study of resting coronary pressure gradient, instantaneous wave-free ratio and fractional flow reserve in an unselected population referred for invasive angiography). Circulation: Cardiovascular Interventions, 9(11), e004016. (doi: 10.1161/CIRCINTERVENTIONS.116.004016) (PMID:27834663)

Rørth, R. et al. (2016) Return to the workforce following first hospitalization for heart failure: a Danish nationwide cohort study. Circulation, 134(14), pp. 999-1009. (doi: 10.1161/CIRCULATIONAHA.116.021859) (PMID:27507406)

Bauersachs, J. et al. (2016) Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 18(9), pp. 1096-1105. (doi: 10.1002/ejhf.586) (PMID:27338866)

Hawkins, N. M. et al. (2016) Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. European Journal of Heart Failure, 18(9), pp. 1162-1171. (doi: 10.1002/ejhf.614) (PMID:27594177)

Carberry, J. et al. (2016) Remote zone extracellular volume and left ventricular remodeling in survivors of st-elevation myocardial infarction. Hypertension, 68(2), pp. 385-391. (doi: 10.1161/HYPERTENSIONAHA.116.07222) (PMID:27354423) (PMCID:PMC4956675)

Ponikowski, P. et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 18(8), pp. 891-975. (doi: 10.1002/ejhf.592) (PMID:27207191)

Wanner, C. et al. (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. New England Journal of Medicine, 375(4), pp. 323-334. (doi: 10.1056/NEJMoa1515920) (PMID:27299675)

Carrick, D. et al. (2016) Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. JCI Insight, 1(6), e85768. (doi: 10.1172/jci.insight.85768) (PMID:27699259) (PMCID:PMC5033815)

Campbell, R. T., Willox, G. P., Jhund, P. S. , Hawkins, N. M., Huang, F., Petrie, M. C. and McMurray, J. J. V. (2016) Reporting of lost to follow-up and treatment discontinuation in device and pharmacotherapy trials in chronic heart failure: a systematic review. Circulation: Heart Failure, 9(5), e002842. (doi: 10.1161/CIRCHEARTFAILURE.115.002842) (PMID:27162229)

Velazquez, E. J. et al. (2016) Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. New England Journal of Medicine, 374(16), pp. 1511-1520. (doi: 10.1056/NEJMoa1602001) (PMID:27040723) (PMCID:PMC4938005)

Lee, M. M.Y. et al. (2016) Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). Open Heart, 3(1), e000371. (doi: 10.1136/openhrt-2015-000371) (PMID:27110377) (PMCID:PMC4838768)

Abdul-Rahim, A. H. , MacIsaac, R. L., Jhund, P. S. , Petrie, M. C. , Lees, K. R. and McMurray, J. J.V. (2016) Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. International Journal of Cardiology, 209, pp. 310-316. (doi: 10.1016/j.ijcard.2016.02.074) (PMID:26913372)

Carrick, D. et al. (2016) Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison to contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. European Heart Journal, 37(13), pp. 1044-1059. (doi: 10.1093/eurheartj/ehv372) (PMID:26261290) (PMCID:PMC4816961)

Hasenfuß, G. et al. (2016) A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet, 387(10025), pp. 1298-1304. (doi: 10.1016/S0140-6736(16)00704-2) (PMID:27025436)

Carrick, D. et al. (2016) Temporal evolution of myocardial hemorrhage and edema in patients after acute ST-elevation myocardial infarction: pathophysiologic insights and clinical implications. Journal of the American Heart Association, 5, e002834. (doi: 10.1161/JAHA.115.002834) (PMID:26908408) (PMCID:PMC4802451)

Ahmed, N. et al. (2016) Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. International Journal of Cardiology, 202, pp. 305-310. (doi: 10.1016/j.ijcard.2015.09.014) (PMID:26418191) (PMCID:PMC4669307)

Carrick, D. et al. (2016) Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction. Circulation: Cardiovascular Imaging, 9(1), e004148. (doi: 10.1161/CIRCIMAGING.115.004148) (PMID:26763281) (PMCID:PMC4718183)

Jackson, C. E. et al. (2016) The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, 18(12), pp. 1491-1498. (doi: 10.1002/ejhf.543) (PMID:27114189)

Mangion, K. et al. (2016) Infarct size and left ventricular remodelling after preventive percutaneous coronary intervention. Heart, 102(24), pp. 1980-1987. (doi: 10.1136/heartjnl-2015-308660) (PMID:27504003) (PMCID:PMC5256395)

Ponikowski, P. et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), pp. 2129-2200. (doi: 10.1093/eurheartj/ehw128) (PMID:27206819)

Stirrat, C. t. et al. (2016) Ferumoxytol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3T. Journal of Cardiovascular Magnetic Resonance, 18(1), 46. (doi: 10.1186/s12968-016-0261-2) (PMID:27465647) (PMCID:PMC4964058)

2015

Nam, J. et al. (2015) Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. Cost Effectiveness and Resource Allocation, 2015(13), 19. (doi: 10.1186/s12962-015-0045-9) (PMID:26578850) (PMCID:PMC4647286)

Zinman, B. et al. (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), pp. 2117-2128. (doi: 10.1056/NEJMoa1504720) (PMID:26378978)

Jolicœur, E. M. et al. (2015) Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction. Journal of the American College of Cardiology, 66(19), pp. 2092-2100. (doi: 10.1016/j.jacc.2015.08.882) (PMID:26541919)

Simpson, J. et al. (2015) Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis. European Journal of Heart Failure, 17(11), pp. 1182-1191. (doi: 10.1002/ejhf.346) (PMID:26358762)

Fisher, M., Petrie, M. , Ambery, P., Donaldson, J., McMurray, J. J.V. and Ye, J. (2015) Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes and Endocrinology, 3(9), pp. 697-703. (doi: 10.1016/s2213-8587(15)00233-8) (PMID:26276240)

Jackson, C. E. et al. (2015) Combined free light chains are novel predictors of prognosis in heart failure. JACC: Heart Failure, 3(8), pp. 618-625. (doi: 10.1016/j.jchf.2015.03.014) (PMID:26251088)

Rush, C. J., Campbell, R. T., Jhund, P. S. , Connolly, E. C., Preiss, D. , Gardner, R. S., Petrie, M. C. and McMurray, J. J.V. (2015) Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC: Heart Failure, 3(8), pp. 603-614. (doi: 10.1016/j.jchf.2015.03.013) (PMID:26251086)

Carrick, D. et al. (2015) Pathophysiology of LV remodeling in survivors of STEMI : inflammation, remote myocardium, and prognosis. JACC: Cardiovascular Imaging, 8(7), pp. 779-789. (doi: 10.1016/j.jcmg.2015.03.007) (PMID:26093923) (PMCID:PMC4509710)

MacDonald, M. R. et al. (2015) Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. European Journal of Heart Failure, 17(7), pp. 725-734. (doi: 10.1002/ejhf.288) (PMID:26011509) (PMCID:PMC4668269)

Petrie, M.C. , Boyle, J.G. and McKay, G.A. (2015) Use of metformin in chronic kidney disease should continue to be based on common sense in the absence of an evidence base. Diabetic Medicine, 32(7), pp. 981-982. (doi: 10.1111/dme.12709) (PMID:25645049)

Al Halabi, S. et al. (2015) Catheter ablation for atrial fibrillation in heart failure patients. JACC: Clinical Electrophysiology, 1(3), pp. 200-209. (doi: 10.1016/j.jacep.2015.02.018) (PMID:26258174) (PMCID:PMC4525704)

Dalzell, J. R., Rocchiccioli, J. P., Weir, R. A.P., Jackson, C. E., Padmanabhan, N., Gardner, R. S., Petrie, M. C. and McMurray, J. J.V. (2015) The emerging potential of the apelin-APJ system in heart failure. Journal of Cardiac Failure, 21(6), pp. 489-498. (doi: 10.1016/j.cardfail.2015.03.007) (PMID:25795508)

Kukulski, T. et al. (2015) Implication of right ventricular dysfunction on long-term outcome in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting with or without surgical ventricular reconstruction. Journal of Thoracic and Cardiovascular Surgery, 149(5), pp. 1312-1321. (doi: 10.1016/j.jtcvs.2014.09.117) (PMID:25451487) (PMCID:PMC4385741)

Campbell, R. T. et al. (2015) Palliative care needs in patients hospitalized with heart failure (PCHF) study: rationale and design. ESC Heart Failure, 2(1), pp. 25-36. (doi: 10.1002/ehf2.12027) (PMID:27347426) (PMCID:PMC4864752)

Badar, A. A. et al. (2015) Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) programme. European Journal of Heart Failure, 17(2), pp. 196-204. (doi: 10.1002/ejhf.221)

Badar, A. A. et al. (2015) The management of patients with aortic regurgitation and severe left ventricular dysfunction: a systematic review. Expert Review of Cardiovascular Therapy, 13(8), pp. 915-922. (doi: 10.1586/14779072.2015.1067139) (PMID:26163051)

Badar, A. A. et al. (2015) Clinical characteristics and outcomes of patients with coronary artery disease and angina. Circulation: Heart Failure, 8(4), pp. 717-724. (doi: 10.1161/CIRCHEARTFAILURE.114.002024) (PMID:26067854)

Carrick, D. et al. (2015) Pathophysiology of myocardial remodeling in survivors of ST-elevation myocardial infarction revealed by native T1 mapping: inflammation, remote myocardium and prognostic significance. Journal of Cardiovascular Magnetic Resonance, 17(Sup 1), Q:52. (doi: 10.1186/1532-429X-17-S1-Q52) (PMCID:PMC4328295)

Carrick, D. et al. (2015) Prognostic significance of infarct core pathology in ST-elevation myocardial infarction survivors revealed by quantitative T2-weighted cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 17(Sup 1), O54. (doi: 10.1186/1532-429X-17-S1-O54) (PMCID:PMC4328590)

Carrick, D. et al. (2015) Prognostic significance of quantitative measures of myocardial infarct pathology using native T1 mapping, in survivors of ST-elevation myocardial infarction. Journal of Cardiovascular Magnetic Resonance, 17(Sup 1), O53. (doi: 10.1186/1532-429X-17-S1-O53) (PMCID:PMC4328908)

Carrick, D. et al. (2015) Prognostic significance of infarct core pathology in ST-elevation myocardial infarction survivors revealed by non-contrast T1 mapping cardiac magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 17(Sup 1), O26. (doi: 10.1186/1532-429X-17-S1-O26) (PMCID:PMC4328668)

Dalzell, J. R., Cannon, J. A., Simpson, J., Gardner, R. S. and Petrie, M. C. (2015) Improving outcomes in peripartum cardiomyopathy. Expert Review of Cardiovascular Therapy, 13(6), pp. 665-671. (doi: 10.1586/14779072.2015.1040767) (PMID:25927492)

Layland, J. et al. (2015) Assessment of fractional flow reserve in patients with recent Non–ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 8(8), e002207. (doi: 10.1161/circinterventions.114.002207) (PMID:26253733)

Mangion, K., Carrick, D., Payne, A., McClure, J. , Mason, M., Petrie, M. , McEntegart, M., Eteiba, H., Oldroyd, K. and Berry, C. (2015) Infarct burden following multivessel PCI vs. infarct-only PCI in patients with acute STEMI: the Glasgow PRAMI CMR sub-study. Journal of Cardiovascular Magnetic Resonance, 17(Sup 1), O9. (doi: 10.1186/1532-429X-17-S1-O9) (PMCID:PMC4328183)

Mangion, K., Carrick, D., Payne, A. R., McClure, J. , Mason, M., Petrie, M. , McEntegart, M., Eteiba, H., Oldroyd, K. G. and Berry, C. (2015) Left ventricular outcomes following multivessel PCI vs. infarct artery-only PCI in patients with acute STEMI: the Glasgow PRAMI CMR sub-study. Journal of Cardiovascular Magnetic Resonance, 17(S1), P104. (doi: 10.1186/1532-429X-17-S1-P104) (PMCID:PMC4328283)

2014

Badar, A. A. et al. (2014) Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 35(48), pp. 3426-3433. (doi: 10.1093/eurheartj/ehu342)

Wong, C.M. et al. (2014) Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). European Heart Journal, 35(39), pp. 2714-2721. (doi: 10.1093/eurheartj/ehu216)

McMinn, J. F., Lang, N. N. , McPhadden, A., Payne, J. R., Petrie, M. C. and Gardner, R. S. (2014) Biomarkers of acute rejection following cardiac transplantation. Biomarkers in Medicine, 8(6), pp. 815-832. (doi: 10.2217/bmm.14.56) (PMID:25224938)

Carrick, D. et al. (2014) A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). Journal of the American College of Cardiology, 63(20), pp. 2088-2098. (doi: 10.1016/j.jacc.2014.02.530) (PMID:24583294) (PMCID:PMC4029071)

Al-Adhami, A., MacFie, A., Mathieson, C., Quasim, I., Smith, R., Craig, S., Gardner, R., Payne, J., Petrie, M. and Haj-Yahia, S. (2014) Ventricular assist devices as rescue therapy in cardiogenic shock after subarachnoid hemorrhage. Annals of Thoracic Surgery, 97(4), pp. 1440-1443. (doi: 10.1016/j.athoracsur.2013.06.102) (PMID:24694427)

Sliwa, K. et al. (2014) EURObservational research programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. European Journal of Heart Failure, 16(5), pp. 583-591. (doi: 10.1002/ejhf.68)

Perez-Moreno, A. C. et al. (2014) Fatigue as a predictor of outcome in patients with heart failure: analysis of CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC: Heart Failure, 2(2), pp. 187-197. (doi: 10.1016/j.jchf.2014.01.001) (PMID:24720928)

Dalzell, J. R., Seed, A., Berry, C. , Whelan, C. J., Petrie, M. C. , Padmanabhan, N., Clarke, A., Biggerstaff, F., Hillier, C. and McMurray, J. J.V. (2014) Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovascular Therapeutics, 32(1), pp. 13-18. (doi: 10.1111/1755-5922.12053) (PMID:24138103)

2013

Wong, C.M. et al. (2013) Clinical characteristics and outcomes of young and very young adults with heart failure: the CHARM programme. Journal of the American College of Cardiology, 62(20), pp. 1845-1854. (doi: 10.1016/j.jacc.2013.05.072)

Layland, J. et al. (2013) TCT-82 Fractional Flow Reserve versus Angiography in Guiding Management to Optimize Outcomes in Non-ST Elevation Myocardial Infarction (FAMOUS - NSTEMI) Clinical Trial: Relationships Between FFR and Angiographic Stenosis Severity at Baseline. Journal of the American College of Cardiology, 62(18), B26. (doi: 10.1016/j.jacc.2013.08.817)

Layland, J. et al. (2013) TCT-84 Fractional Flow Reserve versus Angiography in Guiding Management to Optimize Outcomes in Non-ST Elevation Myocardial Infarction (FAMOUS - NSTEMI) Clinical Trial: Study Design and Baseline Characteristics of Randomized Participants. Journal of the American College of Cardiology, 62(18), B27. (doi: 10.1016/j.jacc.2013.08.1636)

McGeoch, R.J. et al. (2013) Diagnostic utility of cardiac magnetic resonance imaging in STEMI survivors after emergency PCI. International Journal of Cardiology, 168(3), pp. 2933-2934. (doi: 10.1016/j.ijcard.2013.03.179)

Carrick, D. et al. (2013) A randomised controlled trial of deferred stenting versus immediate stenting to prevent no-reflow in acute ST-elevation myocardial infarction. Scottish Medical Journal, 58(3), e41-e41. (doi: 10.1177/0036933013495794)

Jackson, C.E. et al. (2013) Spectral microvolt T-wave alternans testing has no prognostic value in patients recently hospitalized with decompensated heart failure. European Journal of Heart Failure, 15(11), pp. 1253-1261. (doi: 10.1093/eurjhf/hft085)

MacDonald, M.R., McMurray, J.J.V. and Petrie, M.C. (2013) Letter by MacDonald et al regarding article, "catheter ablation of atrial fibrillation". Circulation, 127(4), e433-e433. (doi: 10.1161/CIRCULATIONAHA.112.137604)

2012

Campbell, R.T., Jhund, P.S. , Castagno, D., Hawkins, N.M., Petrie, M.C. and McMurray, J.J.V. (2012) What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-Preserved, and I-PRESERVE? Journal of the American College of Cardiology, 60(23), pp. 2349-2356. (doi: 10.1016/j.jacc.2012.04.064)

Pettit, S.J., Jhund, P.S. , Hawkins, N.M., Gardner, R.S., Haj-Yahia, S., McMurray, J.J.V. and Petrie, M.C. (2012) How small is too small? A systematic review of center volume and outcome after cardiac transplantation. Circulation: Cardiovascular Quality and Outcomes, 5(6), pp. 783-790. (doi: 10.1161/CIRCOUTCOMES.112.966630)

Payne, A. R. et al. (2012) Microvascular resistance predicts myocardial salvage and infarct characteristics in ST-elevation myocardial infarction. Journal of the American Heart Association, 1(4), e002246. (doi: 10.1161/JAHA.112.002246)

Pettit, S. J., Petrie, M. C. , Connelly, D. T., Japp, A. G., Payne, J. R., Haj-Yahia, S. and Gardner, R. S. (2012) Use of implantable cardioverter defibrillators in patients with left ventricular assist devices. European Journal of Heart Failure, 14(7), pp. 696-702. (doi: 10.1093/eurjhf/hfs062) (PMID:22547745)

Castagno, D., Petrie, M.C. , Claggett, B. and McMurray, J. (2012) Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. European Heart Journal, 33(9), pp. 1137-1141. (doi: 10.1093/eurheartj/ehs004)

Castagno, D., Baird-Gunning, J., Jhund, P. , Zoccai, G. B., MacDonald, M. R., Petrie, M. , Gaita, F. and McMurray, J. (2012) Reply to the letter by Dr Erqou regarding "Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients". American Heart Journal, 163(5), e37. (doi: 10.1016/j.ahj.2012.02.022)

MacDonald, M.R., McMurray, J.J.V. and Petrie, M.C. (2012) Catheter ablation for atrial fibrillation. New England Journal of Medicine, 366(11), p. 1060.

Hamm, C. W. et al. (2012) Linee guida ESC per il trattamento delle sindromi coronariche acute nei pazienti senza sopraslivellamento persistente del tratto ST alla presentazione. Task Force per il Trattamento delle Sindromi Coronariche Acute (SCA) nei Pazienti senza Sopraslivellamento Persistente del Tratto ST alla Presentazione della Società Europea di Cardiologia (ESC). Giornale italiano di cardiologia, 13(3), pp. 171-228. (doi: 10.1714/1038.11322) (PMID:22395108)

Jackson, C.E., Myles, R.C. , Cobbe, S.M., Petrie, M.C. and McMurray, J.J.V. (2012) Microvolt T-wave alternans testing has no role at present in guiding therapy for patients at high risk of ventricular arrhythmias. Journal of the American College of Cardiology, 59(9), p. 856. (doi: 10.1016/j.jacc.2011.10.897)

Jackson, C.E. et al. (2012) Microvolt T-wave alternans (MTWA) testing in 'real world' heart failure (HF): a study of prevalence and incremental prognostic value. Heart, 2012(98), A12. (doi: 10.1136/heartjnl-2012-301877b.17)

Jackson, C.E. et al. (2012) Microvolt T-wave alternans testing should be used to guide arrhythmic therapy in heart failure patients: reply. European Journal of Heart Failure, 14(6), p. 678. (doi: 10.1093/eurjhf/hfs077)

Jackson, C.E. et al. (2012) Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. European Journal of Heart Failure, 14(4), pp. 377-386. (doi: 10.1093/eurjhf/hfs010)

2011

Hamm, C. W. et al. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 32(23), pp. 2999-3054. (doi: 10.1093/eurheartj/ehr236) (PMID:21873419)

Hawkins, N.M., Petrie, M.C. , MacDonald, M.R., Jhund, P.S. , Fabbri, L.M., Wikstrand, J. and McMurray, J.J.V. (2011) Heart failure and chronic obstructive pulmonary disease: the quandary of beta-blockers and beta-agonists. Journal of the American College of Cardiology, 57(21), pp. 2127-2138. (doi: 10.1016/j.jacc.2011.02.020)

MacDonald, M.R. et al. (2011) Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the rosiglitazone evaluated for cardiac outcomes and regulation of glycemia in diabetes (RECORD) study. Diabetes Care, 34(6), pp. 1394-1396. (doi: 10.2337/dc10-2398)

Antony, R. et al. (2011) Cardiovascular magnetic resonance activity in the United Kingdom: a survey on behalf of the british society of cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 13(57), (doi: 10.1186/1532-429X-13-57)

Castagno, D., Baird-Gunning, J., Jhund, P.S. , Biondi-Zoccai, G., MacDonald, M.R., Petrie, M.C. , Gaita, F. and McMurray, J.J.V. (2011) Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. American Heart Journal, 162(5), 938-948.e2. (doi: 10.1016/j.ahj.2011.07.030)

Hawkins, N. M., Petrie, M. C. and McMurray, J. J.V. (2011) Selecting patients for cardiac resynchronization therapy: Electrical or mechanical dyssynchrony? In: Cardiac Resynchronization Therapy in Heart Failure. Wolters Kluwer Health. ISBN 9780781798440

Jackson, C.E. et al. (2011) Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure, 13(7), pp. 746-754. (doi: 10.1093/eurjhf/hfr031)

MacDonald, M. R. et al. (2011) Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart, 97(9), pp. 740-747. (doi: 10.1136/hrt.2010.207340)

Velazquez, E.J. et al. (2011) Coronary-artery bypass surgery in patients with left ventricular dysfunction. New England Journal of Medicine, 364(17), pp. 1607-1616. (doi: 10.1056/NEJMoa1100356)

2010

Dalzell, J. R., Petrie, M. C. and Gardner, R. S. (2010) Congestive heart failure. Advances in management. British Medical Journal, 341, c4280. (doi: 10.1136/bmj.c4280) (PMID:20699309)

Fletcher, A. M., Motherwell, D. W., Small, A. D., McCurrach, G. M., Goodfield, N. E.R., Petrie, M. C. , Martin, W. and Cobbe, S. M. (2010) I-123 MIBG cardiac uptake measurements: limitations of collimator choice and scatter correction in the clinical context. Nuclear Medicine Communications, 31(7), pp. 629-636. (doi: 10.1097/MNM.0b013e3283375639) (PMID:20224458)

Dalzell, J. R., Jackson, C. E., Petrie, M. C. and Hogg, K. J. (2010) Acute myocardial infarction due to coronary vasospasm in a heart transplant recipient. American Journal of Emergency Medicine, 28(4), 539.e1-539.e4. (doi: 10.1016/j.ajem.2009.08.007) (PMID:20466261)

Hawkins, N.M., Jhund, P.S., Simpson, C.R., Petrie, M.C., MacDonald, M.R., Dunn, F.G., MacIntyre, K. and McMurray, J.J.V. (2010) Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. European Journal of Heart Failure, 12(1), pp. 17-24. (doi: 10.1093/eurjhf/hfp160)

Hawkins, N. M. et al. (2010) Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. European Journal of Heart Failure, 12(6), pp. 557-565. (doi: 10.1093/eurjhf/hfq040)

MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D. , Bhagra, S., Jhund, P. S. , Petrie, M. C., McMurray, J. J. V. , Petrie, J.R. and McAlister, F. A. (2010) Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care, 33(6), pp. 1213-1218. (doi: 10.2337/dc09-2227)

Shah, A. M. et al. (2010) The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. European Journal of Heart Failure, 12(11), pp. 1229-1237. (doi: 10.1093/eurjhf/hfq179)

Sliwa, K. et al. (2010) Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European Journal of Heart Failure, 12(8), pp. 767-778. (doi: 10.1093/eurjhf/hfq120)

2009

Dalzell, J.R., Jackson, C.E. and Petrie, M.C. (2009) Profound hypokalaemia mimicking acute myocardial infarction. QJM: An International Journal of Medicine, 102(11), pp. 822-824. (doi: 10.1093/qjmed/hcp102) (PMID:19643910)

Hawkins, N. M., Petrie, M. C. , Jhund, P. S. , Chalmers, G. W., Dunn, F. G. and McMurray, J. J.V. (2009) Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European Journal of Heart Failure, 11(2), pp. 130-139. (doi: 10.1093/eurjhf/hfn013)

Hawkins, N.M., MacDonald, M.R., Petrie, M.C., Chalmers, G., Carter, R., Dunn, F.G. and McMurray, J.J. (2009) Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. European Journal of Heart Failure, 11(7), pp. 684-690. (doi: 10.1093/eurjhf/hfp066)

Hawkins, N., Petrie, M. , Burgess, M. and McMurray, J. (2009) Selecting patients for cardiac resynchronization therapy: the fallacy of echocardiographic dyssynchrony. Journal of the American College of Cardiology, 53(21), pp. 1944-1959. (doi: 10.1016/j.jacc.2008.11.062)

Jackson, C.E., Dalzell, J.R., Bezlyak, V., Tsorlalis, I.K., Myles, R.C., Spooner, R., Ford, I., Petrie, M.C., Cobbe, S. and McMurray, J.J. (2009) Red cell distribution width has incremental prognostic value to B-type natriuretic peptide in acute heart failure. European Journal of Heart Failure, 11(12), pp. 1152-1154. (doi: 10.1093/eurjhf/hfp157)

MacDonald, M.R., Petrie, M.C., Fisher, M. and McMurray, J.J.V. (2009) Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports, 6(2), pp. 126-132. (doi: 10.1007/s11897-009-0019-3)

Stanton, T., Hawkins, N. M., Hogg, K. J., Goodfield, N. E.R., Petrie, M. C. and McMurray, J. J.V. (2009) Three-dimensional echocardiography for optimization of cardiac resynchronization therapy: reply. European Heart Journal, 30(4), pp. 505-506. (doi: 10.1093/eurheartj/ehp002)

2008

Balmain, S., Hawkins, N.M., MacDonald, M.R., Dunn, F.G. and Petrie, M.C. (2008) Pericardiocentesis practice in the United Kingdom. International Journal of Clinical Practice, 62(10), pp. 1515-1519. (doi: 10.1111/j.1742-1241.2007.01536.x) (PMID:18036168)

MacDonald, M.R., Hawkins, N.M., Balmain, S., Dalzell, J., McMurray, J.J. and Petrie, M.C. (2008) Transthoracic echocardiography: a survey of current practice in the UK. QJM: An International Journal of Medicine, 101(5), pp. 345-349.

MacDonald, M.R. et al. (2008) Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in Scotland. Circulation: Heart Failure, 1(4), pp. 234-241. (doi: 10.1161/CIRCHEARTFAILURE.108.794008)

MacDonald, M.R., Petrie, M.C., Hawkins, N.M., Petrie, J.R. , Fisher, M., McKelvie, R., Aguilar, D., Krum, H. and McMurray, J.J.V. (2008) Diabetes, left ventricular systolic dysfunction, and chronic heart failure. European Heart Journal, 29(10), pp. 1224-1240. (doi: 10.1093/eurheartj/ehn156)

MacDonald, M.R. et al. (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 29(11), pp. 1377-1385. (doi: 10.1093/eurheartj/ehn153)

Stanton, T., Hawkins, N.M., Hogg, K.J., Goodfield, N.E.R., Petrie, M.C. and McMurray, J.J.V. (2008) How should we optimize cardiac resynchronization therapy? European Heart Journal, 29(20), pp. 2458-2472. (doi: 10.1093/eurheartj/ehn380)

2007

Petrie, M. C. and McMurray, J. J.V. (2007) Dysglycemia and heart failure hospitalization: what is the link? Circulation, 115(11), pp. 1334-1335. (doi: 10.1161/circulationaha.106.685214) (PMID:17372185)

MacDonald, M. R., Petrie, M. C. , Hawkins, N. M. and McMurray, J. J. (2007) Diabetes, left ventricular systolic dysfunction and chronic heart failure. In: Fisher, M. and McMurray, J. J. (eds.) Diabetic Cardiology. Series: Diabetes in practice. John Wiley & Sons, Ltd.: Chichester, pp. 93-134. ISBN 9780470862049 (doi: 10.1002/9780470723807.ch5)

McEntegart, M., Awede, B., Petrie, M. , Sattar, N., Dunn, F., MacFarlane, N. and McMurray, J. (2007) Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. European Heart Journal, 28, pp. 829-835. (doi: 10.1093/eurheartj/ehm033)

Myles, R., Jackson, C., Tsorlalis, I., Petrie, M. , McMurray, J. and Cobbe, S. (2007) Is microvolt T-wave alternans the answer to risk stratification in heart failure? Circulation, 116, pp. 2984-2991. (doi: 10.1161/CIRCULATIONAHA.107.699918) (PMID:18086940)

2006

Hawkins, N. M., Petrie, M. C. , MacDonald, M. R., Hogg, K. J. and McMurray, J. J.V. (2006) QRS duration alone to select patients for cardiac resynchronization therapy: flying in the face of the evidence? European Heart Journal, 27(24), pp. 3074-3075. (doi: 10.1093/eurheartj/ehl386) (PMID:17121753)

MacDonald, M. R., Hawkins, N. M., McMurray, J. J.V. , Dargie, H. J. and Petrie, M. C. (2006) Is CHARM-added candesartan tolerated in 'real-life” patients with advanced chronic heart failure? Journal of Cardiac Failure, 12(6), S126. (doi: 10.1016/j.cardfail.2006.06.434)

Petrie, M.C. , Peels, J.O.J. and Jessurun, G. (2006) The role of covered stents: more than an occasional cameo? Catheterization and Cardiovascular Interventions, 68(1), pp. 21-26. (doi: 10.1002/ccd.20779) (PMID:16770811)

Gardner, R. S., McDonagh, T. A., MacDonald, M., Dargie, H. J., Murday, A. J. and Petrie, M. C. (2006) Who needs a heart transplant? European Heart Journal, 27(7), pp. 770-772. (doi: 10.1093/eurheartj/ehi759) (PMID:16449246)

Cobbe, S., Martin, W., Motherwell, D. and Petrie, M. (2006) I-123-Metaiodobenzylguanidine in chronic heart failure: is there a clinical use? Nuclear Medicine Communications, 27(12), pp. 927-931. (doi: 10.1097/01.mnm.0000251331.48203.74)

2005

Petrie, M. C. , Oldroyd, K. and Zijlstra, F. (2005) I'm sorry Mr Paxman! Scottish Medical Journal, 50(4), pp. 149-150. (doi: 10.1177/003693300505000404) (PMID:16374976)

Voors, A., Petrie, C., Petrie, M. , Charlesworth, A., Hillege, H., Zijlstra, F., McMurray, J. and van Veldhuisen, D. (2005) Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure. European Heart Journal, 26, pp. 1759-1764. (doi: 10.1093/eurheartj/ehi270)

2004

Petrie, M. C. and Zijlstra, F. (2004) Reflections on the Danish Revolution. European Heart Journal, 25(7), pp. 540-542. (doi: 10.1016/j.ehj.2004.01.022) (PMID:15120049)

Bunton, D., Petrie, M. , Hillier, C., Johnston, F. and McMurray, J. (2004) The clinical relevance of adrenomedullin: a promising profile? Pharmacology and Therapeutics, 103, pp. 179-201. (doi: 10.1016/j.pharmthera.2004.07.002)

Petrie, M. , Hogg, K., Caruana, L. and McMurray, J. (2004) Poor concordance of commonly used echocardiographic measures of left ventricular diastolic function in patients with suspected heart failure but preserved systolic function: is there a reliable echocardiographic measure of diastolic dysfunction? Heart, 90, pp. 511-517. (doi: 10.1136/hrt.2003.011403)

2003

Petrie, M. and McMurray, J. (2003) It cannot be cardiac failure because the heart is not enlarged on the chest X-ray. European Journal of Heart Failure, 5(2), pp. 117-119.

2002

Petrie, M. , Caruana, L., Berry, C. and McMurray, J. (2002) "Diastolic heart failure" or heart failure caused by subtle left ventricular systolic dysfunction? Heart, 87, pp. 29-31.

2001

Blue, L. et al. (2001) Randomised controlled trial of specialist nurse intervention in heart failure. British Medical Journal, 323, pp. 715-718. (doi: 10.1136/bmj.323.7315.715)

Caruana, L., Petrie, M. C. , McMurray, J. j. and MacFarlane, N. G. (2001) Altered diaphragm position and function in patients with chronic heart failure. European Journal of Heart Failure, 3(2), pp. 183-187. (doi: 10.1016/S1388-9842(00)00133-1) (PMID:11246055)

Hillier, C., Berry, C. , Petrie, M. C. , O'Dwyer, P. J., Hamilton, C., Brown, A. and McMurray, J. (2001) Effects of urotensin II in human arteries and veins of varying caliber. Circulation, 103, pp. 1378-1381. (doi: 10.1161/01.CIR.103.10.1378) (PMID:11245639)

Hillier, C., Petrie, M. , Love, M. P., Johnston, F., MacLean, M. R. and McMurray, J. J.V. (2001) Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. Clinical Science, 101, pp. 45-51. (doi: 10.1042/cs1010045) (PMID:11410113)

McDonald, J. E., Padmanabhan, N., Petrie, M. C. , Hillier, C., Connell, J. M.C. and McMurray, J. J.V. (2001) Vasoconstrictor Effect of the Angiotensin-Converting Enzyme-Resistant, Chymase-Specific Substrate [Pro11D-Ala12] Angiotensin I in Human Dorsal Hand Veins: In Vivo Demonstration of Non-ACE Production of Angiotensin II in Humans. Circulation, 104(15), pp. 1805-1808. (doi: 10.1161/hc4001.097220) (PMID:11591618)

Petrie, M.C. , Hillier, C., Johnston, F. and McMurray, J.J.V. (2001) Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure. Hypertension, 38, pp. 412-416. (doi: 10.1161/01.HYP.38.3.412) (PMID:11566914)

Petrie, M.C. , McDonald, J.E., Hillier, C., Morton, J.J. and McMurray, J.J.V. (2001) Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans. British Journal of Clinical Pharmacology, 52(2), pp. 165-168. (doi: 10.1046/j.0306-5251.2001.01428.x) (PMID:11488773)

Petrie, M. and McMurray, J. J.V. (2001) Changes in notions about heart failure. Lancet, 358(9280), pp. 432-434. (doi: 10.1016/S0140-6736(01)05664-1) (PMID:11513900)

Petrie, M. C. , Padmanabhan, N., McDonald, J. E., Hillier, C., Connell, J. M.C. and McMurray, J. J.V. (2001) Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. Journal of the American College of Cardiology, 37(4), pp. 1056-1061. (doi: 10.1016/S0735-1097(01)01111-1) (PMID:11263608)

Petrie, M. , Berry, C., Stewart, S. and McMurray, J. (2001) Failing ageing hearts. European Heart Journal, 22, pp. 1978-1990. (doi: 10.1053/euhj.2000.2558)

2000

Shah, M. R. et al. (2000) Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. American Journal of Medicine, 109(6), pp. 489-492. (doi: 10.1016/s0002-9343(00)00529-5) (PMID:11042239)

Caruana, L., Petrie, M.C. , Davie, A.P. and McMurray, J. (2000) Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. British Medical Journal, 321, pp. 215-218. (doi: 10.1136/bmj.321.7255.215)

Petrie, M. C. , Hillier, C., Morton, J. and McMurray, J. J.V. (2000) Adrenomedullin selectively inhibits angiotensin II-induced aldosterone secretion in humans. Journal of Hypertension, 18(1), pp. 61-64. (doi: 10.1097/00004872-200018010-00009) (PMID:10678544)

1999

Darnley, G. M., Gray, A. C., McClure, S. J., Neary, P., Petrie, M. , McMurray, J. J.V. and MacFarlane, N. G. (1999) Effects of resistive breathing on exercise capacity and diaphragm function in patients with ischaemic heart disease. European Journal of Heart Failure, 1(3), pp. 297-300. (doi: 10.1016/s1388-9842(99)00027-6) (PMID:10935679)

Petrie, M. C. , Dawson, N. F., Murdoch, D. R., Davie, A. P. and McMurray, J. J.V. (1999) Failure of women's hearts. Circulation, 99(17), pp. 2334-2341. (doi: 10.1161/01.CIR.99.17.2334) (PMID:10226101)

Petrie, M. C. , McClure, S. J., Love, M. P. and McMurray, J. J.V. (1999) Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin-1. European Journal of Heart Failure, 1(1), pp. 25-29. (doi: 10.1016/s1388-9842(98)00013-0) (PMID:10937975)

1998

McMurray, J.J. , Petrie, M.C. , Murdoch, D.R. and Davie, A.P. (1998) Clinical epidemiology of heart failure: public and private health burden. European Heart Journal, 19 Sup, P9-16. (PMID:9886707)

Articles

Osmanska, J., Petrie, M. C. , Docherty, K. F. , Lee, M. M.Y. , McMurray, J. J.V. and Campbell, R. (2024) Subcutaneous furosemide in heart failure: a systematic review. European Heart Journal: Cardiovascular Pharmacotherapy, (doi: 10.1093/ehjcvp/pvae083) (Accepted for Publication)

Averbuch, T., Lee, S. F., Zagorski, B., Pandey, A., Petrie, M. C. , Biering‐Sorensen, T., Xie, F. and Van Spall, H. G.C. (2024) Long‐term clinical outcomes and healthcare resource utilization in male and female patients following hospitalization for heart failure. European Journal of Heart Failure, (doi: 10.1002/ejhf.3499) (PMID:39498574) (Early Online Publication)

Foley, P.W. et al. (2024) Effect of correcting iron deficiency on the risk of serious infection in heart failure insights from the IRONMAN trial. European Journal of Heart Failure, (doi: 10.1002/ejhf.3504) (PMID:39453738) (Early Online Publication)

Lee, M. et al. (2024) Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic – insights from the IRONMAN trial. European Journal of Heart Failure, 26(10), pp. 2293-2295. (doi: 10.1002/ejhf.3394) (PMID:39078467)

Sliwa, K. et al. (2024) Living with peripartum cardiomyopathy: A statement from the Heart Failure Association and the Association of Cardiovascular Nursing and Allied Professions of the European Society of Cardiology. European Journal of Heart Failure, 26(10), pp. 2143-2154. (doi: 10.1002/ejhf.3377) (PMID:39115028)

Ryan, M. et al. (2024) Effect of PCI on health status in ischemic left ventricular dysfunction: insights from REVIVED-BCIS2. JACC: Heart Failure, 12(9), pp. 1553-1562. (doi: 10.1016/j.jchf.2024.03.010) (PMID:38727649)

Seferović, P. M. et al. (2024) Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases. European Journal of Heart Failure, 26(9), pp. 1893-1903. (doi: 10.1002/ejhf.3347) (PMID:38896048)

van der Meer, P. et al. (2024) Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry. European Heart Journal, (doi: 10.1093/eurheartj/ehae559) (PMID:39221911) (Accepted for Publication)

Ponikowski, P. et al. (2024) Hospitalization of symptomatic patients with heart failure and moderate to severe functional mitral regurgitation treated with MitraClip: insights from RESHAPE-HF2. JACC: Heart Failure, (doi: 10.1016/j.jacc.2024.08.027) (PMID:39217574) (In Press)

Carberry, J. et al. (2024) Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, 11(4), pp. 2001-2012. (doi: 10.1002/ehf2.14830) (PMID:38715187) (PMCID:PMC11287338)

Docherty, K. F. , McMurray, J. J.V. , Kalra, P., Cleland, J. G.F. , Lang, N. N. , Petrie, M. C. , Robertson, M. and Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11(4), pp. 1875-1879. (doi: 10.1002/ehf2.14742) (PMID:38549192) (PMCID:PMC11287326)

Gustafsson, F. et al. (2024) 2-year outcomes of an atrial shunt device in HFpEF/HFmrEF: results from REDUCE LAP-HF II. JACC: Heart Failure, 12(8), pp. 1425-1438. (doi: 10.1016/j.jchf.2024.04.011) (PMID:38934964)

Rosano, G. M.C. et al. (2024) Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC. European Journal of Heart Failure, 26(8), pp. 1669-1686. (doi: 10.1002/ejhf.3284) (PMID:38783694)

Zahir Anjum, D. et al. (2024) Use of medical therapy and risk of clinical events according to frailty in heart failure patients – A real‐life cohort study. European Journal of Heart Failure, 26(8), pp. 1717-1726. (doi: 10.1002/ejhf.3249) (PMID:38700461)

Ezad, S. M. et al. (2024) Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy. Journal of the American College of Cardiology, 84(4), pp. 340-350. (doi: 10.1016/j.jacc.2024.04.043) (PMID:38759904) (PMCID:PMC11250908)

Schou, M. et al. (2024) Semaglutide and NYHA functional class in obesity-related heart failure with preserved ejection fraction the STEP-HFpEF program. Journal of the American College of Cardiology, 84(3), pp. 247-257. (doi: 10.1016/j.jacc.2024.04.038) (PMID:38913004)

Anker, S. D. et al. (2024) Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials. European Journal of Heart Failure, 26(7), pp. 1608-1615. (doi: 10.1002/ejhf.3286) (PMID:38847420)

Savarese, G. et al. (2024) Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice. European Journal of Heart Failure, 26(6), pp. 1408-1418. (doi: 10.1002/ejhf.3214) (PMID:38515385)

Udell, J. A. et al. (2024) Left ventricular function, congestion, and effect of empagliflozin on heart failure risk after myocardial infarction. Journal of the American College of Cardiology, 83(23), pp. 2233-2246. (doi: 10.1016/j.jacc.2024.03.405) (PMID:38588929)

Rankin, S. et al. (2024) Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using 18F-FDG positron emission tomography. bioRxiv, (doi: 10.1101/2024.05.30.596741)

Curtain, J. P. et al. (2024) Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF. European Journal of Heart Failure, 26(6), pp. 1383-1392. (doi: 10.1002/ejhf.3290) (PMID:38741283)

Hernandez, A. F. et al. (2024) Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial. Circulation, 149(21), pp. 1627-1638. (doi: 10.1161/circulationaha.124.069217) (PMID:38581389) (PMCID:PMC11115458)

Ray, R. et al. (2024) The impact of ferric derisomaltose on cardiovascular and non-cardiovascular events in patients with anemia, iron deficiency and heart failure with reduced ejection fraction. Journal of Cardiac Failure, 30(5), pp. 682-690. (doi: 10.1016/j.cardfail.2023.10.006) (PMID:37926238) (PMCID:PMC11096866)

Butler, J. et al. (2024) Empagliflozin after acute myocardial infarction. New England Journal of Medicine, 390(16), pp. 1455-1466. (doi: 10.1056/NEJMoa2314051) (PMID:38587237)

Butler, J. et al. (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet, 403(10437), pp. 1635-1648. (doi: 10.1016/S0140-6736(24)00469-0) (PMID:38599221)

Kosiborod, M. N. et al. (2024) Semaglutide in patients with obesity-related heart failure and type 2 diabetes. New England Journal of Medicine, 390(15), pp. 1394-1407. (doi: 10.1056/NEJMoa2313917) (PMID:38587233)

Rankin, S., Elyan, B. , Jones, R. , Venugopal, B., Mark, P. B. , Lees, J. S. , Petrie, M. C. and Lang, N. N. (2024) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, 6(2), pp. 267-279. (doi: 10.1016/j.jaccao.2023.12.010) (PMID:38774021) (PMCID:PMC11103039)

Glen, C. et al. (2024) Cardiovascular sequalae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart, 110(9), pp. 650-656. (doi: 10.1136/heartjnl-2023-323437) (PMID:38103912) (PMCID:PMC11041571)

Jackson, A. M. et al. (2024) A novel score to predict left ventricular recovery in peripartum cardiomyopathy derived from the ESC EORP Peripartum Cardiomyopathy Registry. European Heart Journal, 45(16), pp. 1430-1439. (doi: 10.1093/eurheartj/ehad888) (PMID:38282532) (PMCID:PMC11032708)

Osmanska, J., Petrie, M. C. and Campbell, R. T. (2024) Reply: subcutaneous furosemide patch: heart failure decongestion "from the comfort of your home". European Heart Journal: Cardiovascular Pharmacotherapy, 10(3), pp. 261-262. (doi: 10.1093/ehjcvp/pvae015) (PMID:38366161)

Knigge, P. et al. (2024) Temporal trends in the initiation of dialysis among patients with heart failure with or without diabetes: a nationwide study from 2002 to 2016. Journal of the American Heart Association, 13(6), e032539. (doi: 10.1161/JAHA.123.032539) (PMID:38471834) (PMCID:PMC11009989)

Campbell, P., Rutten, F. H., Lee, M. M. Y. , Hawkins, N. M. and Petrie, M. C. (2024) Heart failure with preserved ejection fraction: Everything the clinician needs to know. Lancet, 403(10431), pp. 1083-1092. (doi: 10.1016/S0140-6736(23)02756-3) (PMID:38367642)

Sliwa, K. et al. (2024) Socio-economic factors determine maternal and neonatal outcomes in women with peripartum cardiomyopathy: a study of the ESC EORP PPCM registry. International Journal of Cardiology, 398, 131596. (doi: 10.1016/j.ijcard.2023.131596) (PMID:37979788)

Deo, S. V. et al. (2024) Impact of residential social deprivation on prediction of heart failure in patients with type 2 diabetes: External validation and recalibration of the WATCH-DM score using real world data. Circulation: Cardiovascular Quality and Outcomes, 17(3), pp. 267-276. e010166. (doi: 10.1161/circoutcomes.123.010166) (PMID:38328913)

Mellbin, L. G., Bhatt, D. L., David, J.-P., Ekström, K., Petrie, M. C. , Rasmussen, S. and Vilsbøll, T. (2024) Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials. European Heart Journal, 45(15), pp. 1371-1374. (doi: 10.1093/eurheartj/ehae028) (PMID:38416593) (PMCID:PMC11015952)

Rudd, A. E. et al. (2024) Cardiovascular and noncardiovascular prescribing and mortality after takotsubo comparison with myocardial infarction and general population. JACC: Advances, 3(2), 100797. (doi: 10.1016/j.jacadv.2023.100797)

UK HFpEF Collaborative Group, and , (2024) Rationale and design of the United Kingdom Heart Failure with Preserved Ejection Fraction Registry. Heart, 110(5), pp. 359-365. (doi: 10.1136/heartjnl-2023-323049) (PMID:37827557)

Black, N. et al. (2024) Development and validation of imaging-free myocardial fibrosis prediction models, association with outcomes, and sample size estimation for phase 3 trials. medRxiv, (doi: 10.1101/2024.02.07.24302443)

Butt, J. H. et al. (2024) Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan. ESC Heart Failure, 11(1), pp. 65-77. (doi: 10.1002/ehf2.14558) (PMID:37813587) (PMCID:PMC10804200)

Vardeny, O. et al. (2024) Dapagliflozin and mode of death in heart failure with improved ejection fraction: A post hoc analysis of the DELIVER trial. JAMA Cardiology, 9(3), pp. 283-289. (doi: 10.1001/jamacardio.2023.5318) (PMID:38265835) (PMCID:PMC10809142)

Omerovic, E. et al. (2024) Pragmatic randomized controlled trials: strengthening the concept through a robust international collaborative network: PRIME-9-pragmatic research and innovation through multinational experimentation. Trials, 25, 80. (doi: 10.1186/s13063-024-07935-y) (PMID:38263138) (PMCID:PMC10807265)

Petrie, M. C. et al. (2024) Pulmonary congestion and left ventricular dysfunction after myocardial infarction: insights from the PARADISE-MI trial. Circulation, 149(4), pp. 335-38. (doi: 10.1161/CIRCULATIONAHA.123.066163) (PMID:38252738)

Kosiborod, M. N. et al. (2024) Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation, 149(3), pp. 204-216. (doi: 10.1161/circulationaha.123.067505) (PMID:37952180) (PMCID:PMC10782938)

Chivardi, C. et al. (2024) Percutaneous revascularization for ischemic left ventricular dysfunction: Cost-effectiveness analysis of the REVIVED-BCIS2 trial. Circulation: Cardiovascular Quality and Outcomes, 17(1), e010533. (doi: 10.1161/circoutcomes.123.010533) (PMID:37929587) (PMCID:PMC10782932)

Jackson, A. et al. (2024) Outcomes at one year in women with peripartum cardiomyopathy: findings from the ESC EORP PPCM Registry. European Journal of Heart Failure, 26(1), pp. 34-42. (doi: 10.1002/ejhf.3055) (PMID:37823238)

Lee, M. M.Y. , Kondo, T., Campbell, R. T., Petrie, M. C. , Sattar, N. , Solomon, S. D., Vaduganathan, M., Jhund, P. S. and McMurray, J. J.V. (2024) Effects of Renin-Angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomised controlled trials. European Heart Journal: Cardiovascular Pharmacotherapy, 10(1), pp. 68-80. (doi: 10.1093/ehjcvp/pvad067) (PMID:37740450) (PMCID:PMC10766905)

McDowell, K., Adamson, C., Jackson, C., Campbell, R., Welsh, P. , Petrie, M. C. , McMurray, J. J.V. , Jhund, P. and Herring, N. (2024) Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. European Journal of Heart Failure, 26(1), pp. 107-116. (doi: 10.1002/ejhf.3085) (PMID:37937329)

Osmanska, J. et al. (2024) A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. European Heart Journal: Cardiovascular Pharmacotherapy, 10, pp. 35-44. (doi: 10.1093/ehjcvp/pvad073) (PMID:37804170) (PMCID:PMC10766906)

Lee, M. M.Y. , Lean, M. E.J. , Sattar, N. and Petrie, M. C. (2023) Appetite and its regulation: Are there palatable interventions for heart failure? Current Heart Failure Reports, 21, pp. 1-4. (doi: 10.1007/s11897-023-00637-7) (PMID:38133864) (PMCID:PMC10827951)

Jackson, A. M. et al. (2023) A 20-year population study of peripartum cardiomyopathy. European Heart Journal, 44(48), pp. 5128-5141. (doi: 10.1093/eurheartj/ehad626) (PMID:37804234) (PMCID:PMC10733720)

Kosiborod, M. N., Borlaug, B. A. and Petrie, M. C. (2023) Semaglutide and heart failure with preserved ejection fraction and obesity. Reply. New England Journal of Medicine, 389(25), pp. 2398-2399. (doi: 10.1056/NEJMc2312296) (PMID:38118037)

Zahir Anjum, D. et al. (2023) Initiation of medical therapy for heart failure patients according to kidney function: a Danish nationwide study. Clinical Epidemiology, 15, pp. 855-866. (doi: 10.2147/clep.s412787) (PMID:37489222) (PMCID:PMC10363354)

Glen, C., Adam, S., McDowell, K., Waterston, A., Tan, Y. Y., Petrie, M. C. , Coats, C. J. and Lang, N. N. (2023) Cardiotoxicity of BRAF/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores. JACC: CardioOncology, 5(5), pp. 628-637. (doi: 10.1016/j.jaccao.2023.04.004) (PMID:37969652) (PMCID:PMC10635885)

Malik, M. E. et al. (2023) Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longevity, 4(10), e552-e560. (doi: 10.1016/S2666-7568(23)00164-2) (PMID:37734395)

Nadarajah, R. et al. (2023) Prediction models for heart failure in the community: a systematic review and meta‐analysis. European Journal of Heart Failure, 25(10), pp. 1724-1738. (doi: 10.1002/ejhf.2970) (PMID:37403669)

Seckin, M., Johnston, B. , Petrie, M. C. , Stewart, S. and Chan, Y.-K. (2023) Characteristics of symptoms and symptom change across different heart failure subtypes: a sex-stratified analysis. European Journal of Cardiovascular Nursing, 22(7), pp. 690-700. (doi: 10.1093/eurjcn/zvac099) (PMID:36288919)

Perera, D. et al. (2023) Arrhythmia and death following percutaneous revascularization in ischemic left ventricular dysfunction: Prespecified analyses from the REVIVED-BCIS2 trial. Circulation: Heart Failure, 148(11), pp. 862-871. (doi: 10.1161/circulationaha.123.065300) (PMID:37555345) (PMCID:PMC10487377)

Harrington, J. et al. (2023) Baseline characteristics of patients enrolled in the EMPACT‐MI trial. European Journal of Heart Failure, 25(9), pp. 1708-1715. (doi: 10.1002/ejhf.2990) (PMID:37622416)

Borlaug, B. A. et al. (2023) Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nature Medicine, 29(9), pp. 2358-2365. (doi: 10.1038/s41591-023-02526-x) (PMID:37635157) (PMCID:PMC10504076)

Ioannou, A. et al. (2023) Conventional heart failure therapy in cardiac ATTR amyloidosis. European Heart Journal, 44(31), pp. 2893-2907. (doi: 10.1093/eurheartj/ehad347) (PMID:37216684) (PMCID:PMC10424879)

Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)

Docherty, K. F. , Jackson, A. M., Macartney, M., Campbell, R. T., Petrie, M. C. , Pfeffer, M. A., McMurray, J. J.V. and Jhund, P. S. (2023) Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016. European Journal of Heart Failure, 25(8), pp. 1213-1224. (doi: 10.1002/ejhf.2965) (PMID:37401485)

Docherty, K. F. , Lam, C. S.P., Rakisheva, A., Coats, A. J.S., Greenhalgh, T., Metra, M., Petrie, M. C. and Rosano, G. M.C. (2023) Heart failure diagnosis in the general community - who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 25(8), pp. 1185-1198. (doi: 10.1002/ejhf.2946) (PMID:37368511)

Tromp, J., Jackson, A. M., Abdelhamid, M., Fouad, D., Youssef, G., Petrie, M. C. , Bauersachs, J., Sliwa, K. and van der Meer, P. (2023) Thrombo‐embolic events in peripartum cardiomyopathy: results from the ESC EORP PPCM registry. European Journal of Heart Failure, 25(8), pp. 1464-1466. (doi: 10.1002/ejhf.2871) (PMID:37092321)

Araki, T. et al. (2023) Relationship between the volume of cases and in-hospital mortality in patients with cardiogenic shock receiving short-term mechanical circulatory support. American Heart Journal, 261, pp. 109-123. (doi: 10.1016/j.ahj.2023.03.017) (PMID:37031832)

Kondo, T. et al. (2023) Predicting stroke in heart failure and preserved ejection fraction without atrial fibrillation. Circulation: Heart Failure, 16(7), e010377. (doi: 10.1161/CIRCHEARTFAILURE.122.010377) (PMID:37350280)

Curtain, J. P., Lee, M. M.Y. , McMurray, J. J.V. , Gardner, R. S., Petrie, M. C. and Jhund, P. S. (2023) Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. Heart, 109(11), pp. 823-831. (doi: 10.1136/heartjnl-2022-321885) (PMID:36522146) (PMCID:PMC10314022)

Gard, E. K. et al. (2023) Left atrial enlargement is associated with pulmonary vascular disease in heart failure with preserved ejection fraction. European Journal of Heart Failure, 25(6), pp. 806-814. (doi: 10.1002/ejhf.2805) (PMID:36847073)

Lam, C. S. P., Harding, E., Bains, M., Chin, A., Kanumilli, N., Petrie, M. C. , Pohja-Hutchison, P., Yang, J. and Butler, J. (2023) Identification of urgent gaps in public and policymaker knowledge of heart failure: results of a global survey. BMC Public Health, 23, 1023. (doi: 10.1186/s12889-023-15405-4) (PMID:37254075) (PMCID:PMC10227786)

Dewan, P. et al. (2023) Impact of multimorbidity on mortality in HFrEF : which comorbidities matter most? – an analysis of PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 25(5), pp. 687-697. (doi: 10.1002/ejhf.2856) (PMID:37062869)

Butler, J. et al. (2023) Challenges and opportunities for increasing patient involvement in heart failure self-care programs and self-care in the post–hospital discharge period. Research Involvement and Engagement, 9, 23. (doi: 10.1186/s40900-023-00412-x) (PMID:37046357) (PMCID:PMC10097448)

Bruhn, J. et al. (2023) Temporal trends in the incidence of malignancy in heart failure: a nationwide Danish study. European Heart Journal, 44(13), pp. 1124-1132. (doi: 10.1093/eurheartj/ehac797) (PMID:36691953)

Butt, J. H. et al. (2023) Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. European Heart Journal, 44(13), pp. 1136-1153. (doi: 10.1093/eurheartj/ehad083) (PMID:36944496) (PMCID:PMC10111968)

Desai, A. S. and Petrie, M. C. (2023) Centrally adjudicated heart failure outcomes are needed in clinical trials. JACC: Heart Failure, 11(4), pp. 418-421. (doi: 10.1016/j.jchf.2023.01.028) (PMID:37019557)

Dobbin, S. J.H. , Shen, L., Petrie, M. C. , Packer, M., Solomon, S. D., McMurray, J. J.V. , Lang, N. N. and Jhund, P. S. (2023) Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. European Journal of Heart Failure, 25(4), pp. 488-496. (doi: 10.1002/ejhf.2818) (PMID:36919816)

Mooney, L., Jackson, C. E., Adamson, C., McConnachie, A. , Welsh, P. , Myles, R. C. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Lang, N. N. (2023) Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circulation: Heart Failure, 16(4), e010051. (doi: 10.1161/CIRCHEARTFAILURE.122.010051) (PMID:36896709) (PMCID:PMC10101136)

Curtain, J. P. et al. (2023) Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. European Heart Journal, 44(8), pp. 668-677. (doi: 10.1093/eurheartj/ehac801) (PMID:36632831)

Pathak, S., Lai, F. Y., Miksza, J., Petrie, M. C. , Roman, M., Murray, S., Dearling, J., Perera, D. and Murphy, G. J. (2023) Surgical or percutaneous coronary revascularization for heart failure: an in silico model using routinely collected health data to emulate a clinical trial. European Heart Journal, 44(5), pp. 351-364. (doi: 10.1093/eurheartj/ehac670) (PMID:36350978) (PMCID:PMC9890210)

Kondo, T. et al. (2023) Prognosis in patients with cardiogenic shock who received temporary mechanical circulatory support. JACC: Asia, 3(1), pp. 122-134. (doi: 10.1016/j.jacasi.2022.10.004) (PMID:36873766) (PMCID:PMC9982290)

Petrie, M. C. et al. (2023) High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovascular Research, 119(1), pp. 213-220. (doi: 10.1093/cvr/cvab317) (PMID:34875022) (PMCID:PMC10022850)

Perera, D. et al. (2023) Viability and outcomes with revascularization or medical therapy in ischemic ventricular dysfunction: a prespecified secondary analysis of the REVIVED-BCIS2 Trial. JAMA Cardiology, 8(12), pp. 1154-1161. (doi: 10.1001/jamacardio.2023.3803) (PMID:37878295) (PMCID:PMC10600721)

Kalra, P. R. et al. (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet, 400(10369), pp. 2199-2209. (doi: 10.1016/S0140-6736(22)02083-9) (PMID:36347265)

Mehran, R. et al. (2022) The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE-MI trial. Circulation, 146(23), pp. 1749-1757. (doi: 10.1161/CIRCULATIONAHA.122.060841) (PMID:36321459)

Gregers, M. C. T., Schou, M., Jensen, M. T., Jensen, J., Petrie, M. C. , Vilsbøll, T., Goetze, J. P., Rossing, P. and Jørgensen, P. G. (2022) Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes. Scandinavian Cardiovascular Journal, 56(1), pp. 256-263. (doi: 10.1080/14017431.2022.2095435) (PMID:35811473)

Kalra, P. R. et al. (2022) Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart, 108(24), pp. 1979-1985. (doi: 10.1136/heartjnl-2022-321304) (PMID:35948408) (PMCID:PMC9726969)

Mark, P. B. , Mangion, K., Rankin, A. J. , Rutherford, E., Lang, N. N. , Petrie, M. C. , Stoumpos, S. and Patel, R. K. (2022) Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. Clinical Kidney Journal, 15(12), pp. 2186-2199. (doi: 10.1093/ckj/sfac146) (PMID:36381379) (PMCID:PMC9664574)

Tromp, J., Bauer, D., Claggett, B. L., Frost, M., Iversen, M. B., Prasad, N., Petrie, M. C. , Larson, M. G., Ezekowitz, J. A. and Solomon, S. D. (2022) A formal validation of a deep learning-based automated workflow for the interpretation of the echocardiogram. Nature Communications, 13, 6776. (doi: 10.1038/s41467-022-34245-1) (PMID:36351912) (PMCID:PMC9646849)

Kondo, T. et al. (2022) Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. European Heart Journal, 43(42), pp. 4469-4479. (doi: 10.1093/eurheartj/ehac487) (PMID:36017729) (PMCID:PMC9637422)

Arulmurugananthavadivel, A. et al. (2022) Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark 1997–2017. European Heart Journal: Quality of Care and Clinical Outcomes, 8(7), pp. 750-760. (doi: 10.1093/ehjqcco/qcab073) (PMID:34625809) (PMCID:PMC9603536)

Harrington, J. et al. (2022) Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. American Heart Journal, 253, pp. 86-98. (doi: 10.1016/j.ahj.2022.05.010) (PMID:35595091)

Garred, C. H. et al. (2022) Adherence and discontinuation of optimal heart failure therapies according to age: a Danish nationwide study. Journal of the American Heart Association, 11(19), e026187. (doi: 10.1161/JAHA.122.026187) (PMID:36172925) (PMCID:PMC9673698)

Desai, A. S. et al. (2022) Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction. JAMA Cardiology, 7(12), pp. 1227-1234. (doi: 10.1001/jamacardio.2022.3736) (PMID:36189985) (PMCID:PMC9531084)

Harrington, J., Petrie, M. C. , Anker, S. D., Bhatt, D. L., Jones, S. W., Udell, J. A., Hernandez, A. F. and Butler, J. (2022) Evaluating the application of chronic heart failure therapies and developing treatments in individuals with recent myocardial infarction. JAMA Cardiology, 7(10), pp. 1067-1075. (doi: 10.1001/jamacardio.2022.2847) (PMID:36044233)

Welsh, P. et al. (2022) Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort. Circulation: Heart Failure, 15(10), pp. 957-967. (doi: 10.1161/CIRCHEARTFAILURE.121.009427) (PMID:36098049) (PMCID:PMC9561238)

Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)

Hoes, M. F., Arany, Z., Bauersachs, J., Hilfiker-Kleiner, D., Petrie, M. C. , Sliwa, K. and van der Meer, P. (2022) Pathophysiology and risk factors of peripartum cardiomyopathy. Nature Reviews Cardiology, 19(8), pp. 555-565. (doi: 10.1038/s41569-021-00664-8) (PMID:35017720)

Ryan, M., Perera, D. and Petrie, M. C. (2022) Revascularisation and HFpEF – time for randomised trials. European Journal of Heart Failure, 24(8), pp. 1439-1440. (doi: 10.1002/ejhf.2583) (PMID:35729798)

Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)

Shen, L. et al. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)

Curtain, J. P. et al. (2022) Clinical outcomes related to background diuretic use and new diuretic initiation in patients with HFrEF. JACC: Heart Failure, 10(6), pp. 415-427. (doi: 10.1016/j.jchf.2022.01.020) (PMID:35654526)

Jackson, A. M., Benson, L., Savarese, G., Hage, C., Jhund, P. S. , Petrie, M. C. , Dahlström, U., McMurray, J. J.V. and Lund, L. H. (2022) Apparent treatment-resistant hypertension across the spectrum of heart failure phenotypes in the Swedish HF Registry. JACC: Heart Failure, 10(6), pp. 380-392. (doi: 10.1016/j.jchf.2022.04.006) (PMID:35654522)

Borlaug, B. A. et al. (2022) Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure. Circulation, 145(21), pp. 1592-1604. (doi: 10.1161/CIRCULATIONAHA.122.059486) (PMID:35354306) (PMCID:PMC9133195)

Udell, J. A., Jones, W. S., Petrie, M. C. , Harrington, J., Anker, S. D., Bhatt, D. L., Hernandez, A. F. and Butler, J. (2022) Sodium glucose cotransporter-2 inhibition for acute myocardial infarction: JACC Review Topic of the Week. Journal of the American College of Cardiology, 79(20), pp. 2058-2068. (doi: 10.1016/j.jacc.2022.03.353) (PMID:35589167) (PMCID:PMC8972442)

Cohen, D. J. et al. (2022) Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation. Heart, 108(9), pp. 717-724. (doi: 10.1136/heartjnl-2021-320005) (PMID:35078867) (PMCID:PMC8995818)

He, W. et al. (2022) Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size. Cardiovascular Research, 118(6), pp. 1535-1547. (doi: 10.1093/cvr/cvab204) (PMID:34132807)

Yeoh, S. E. et al. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)

Cotton, S. et al. (2022) Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 23, 307. (doi: 10.1186/s13063-022-06226-8) (PMID:35422024) (PMCID:PMC9009490)

Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)

Curtain, J. P. et al. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J. , Jones, R. J. , Petrie, M. C. and Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4(1), pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096) (PMID:35492830) (PMCID:PMC9040125)

Jackson, A. M. et al. (2022) Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 24(3), pp. 497-509. (doi: 10.1002/ejhf.2403) (PMID:34918855) (PMCID:PMC9542636)

Lee, M. M.Y. et al. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)

Deis, T. et al. (2022) Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction. ESC Heart Failure, 9(1), pp. 186-195. (doi: 10.1002/ehf2.13697) (PMID:34877822) (PMCID:PMC8788022)

Docherty, K. F. and Petrie, M. C. (2022) Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 108(4), pp. 312-320. (doi: 10.1136/heartjnl-2020-318658) (PMID:34127540)

Januzzi, J. L. et al. (2022) Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. Journal of Hematology and Oncology, 15(1), 1. (doi: 10.1186/s13045-021-01221-z) (PMID:34991679) (PMCID:PMC8734305)

Pfeffer, M. A. et al. (2022) Impact of sacubitril/valsartan versus ramipril on total heart failure events in the PARADISE-MI trial. Circulation, 145(1), pp. 87-89. (doi: 10.1161/CIRCULATIONAHA.121.057429) (PMID:34797725)

Chan, Y., Seckin, M., Johnston, B., Petrie, M. and Stewart, S. (2022) Characteristics of symptom change in men and women with different heart failure subtypes. Heart, Lung and Circulation, 31(Suppl3), S76. (doi: 10.1016/j.hlc.2022.06.074)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Diamant, M. J., Andrade, J. G., Virani, S. A., Jhund, P. S. , Petrie, M. C. and Hawkins, N. M. (2021) Heart failure and atrial flutter: a systematic review of current knowledge and practices. ESC Heart Failure, 8(6), pp. 4484-4496. (doi: 10.1002/ehf2.13526) (PMID:34505352) (PMCID:PMC8712920)

Jackson, A. M. et al. (2021) Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. European Journal of Heart Failure, 23(12), pp. 2058-2069. (doi: 10.1002/ejhf.2264) (PMID:34114268)

Mark, P. B. et al. (2021) Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. Kidney360, 2(11), pp. 1761-1769. (doi: 10.34067/KID.0004272021)

Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)

Rush, C. J. et al. (2021) Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiology, 6(10), pp. 1130-1143. (doi: 10.1001/jamacardio.2021.1825) (PMID:34160566) (PMCID:PMC8223134)

Curtain, J. P. et al. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)

Rørth, R. et al. (2021) Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. PLoS ONE, 16(8), e0255364. (doi: 10.1371/journal.pone.0255364) (PMID:34347805) (PMCID:PMC8336831)

Graham, F. J., Pellicori, P. , Ford, I. , Petrie, M. C. , Kalra, P. R. and Cleland, J. G.F. (2021) Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clinical Research in Cardiology, 110(8), pp. 1299-1307. (doi: 10.1007/s00392-021-01837-8) (PMID:33755777)

Petrie, M. C. , Lee, M. M.Y. and Docherty, K. F. (2021) Sodium–glucose co-transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction? European Journal of Heart Failure, 23(8), pp. 1256-1259. (doi: 10.1002/ejhf.2108) (PMID:33502794)

Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)

Lee, M. M.Y. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Sattar, N. (2021) Response by Lee et al to letter regarding article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". Circulation, 144(3), e40. (doi: 10.1161/CIRCULATIONAHA.121.055067) (PMID:34279995)

Jhund, P. S. et al. (2021) Heart failure hospitalization in adults receiving maintenance hemodialysis and effect of intravenous iron therapy: A report from PIVOTAL. JACC: Heart Failure, 9(7), pp. 518-527. (doi: 10.1016/j.jchf.2021.04.005) (PMID:34119470)

Simpson, J. et al. (2021) Adherence to prescribed medications in patients with heart failure – insights from liquid chromatography-tandem mass spectrometry-based urine analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 7(4), pp. 296-301. (doi: 10.1093/ehjcvp/pvaa071) (PMID:32597982) (PMCID:PMC8302254)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)

Maznyczka, A. M. et al. (2021) Thermodilution-derived temperature recovery time, a novel predictor of microvascular reperfusion and prognosis after myocardial infarction. EuroIntervention, 17(3), pp. 220-228. (doi: 10.4244/EIJ-D-19-00904) (PMID:32122822)

Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)

Rossitto, G. et al. (2021) High sodium intake, glomerular hyperfiltration and protein catabolism in patients with essential hypertension. Cardiovascular Research, 117(5), pp. 1372-1381. (doi: 10.1093/cvr/cvaa205) (PMID:33053160) (PMCID:PMC8064429)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)

Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)

Mbakwem, A. C. et al. (2021) Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy: results from the ESC EORP PPCM registry. ESC Heart Failure, 8(2), pp. 879-889. (doi: 10.1002/ehf2.13172) (PMID:33453082) (PMCID:PMC8006717)

Mooney, L., Goodyear, C. S. , Chandra, T., Kirschner, K. , Copland, M. , Petrie, M. C. and Lang, N. N. (2021) Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. Clinical Science, 135(7), pp. 991-1007. (doi: 10.1042/CS20200306) (PMID:33861346) (PMCID:PMC8055963)

Sliwa, K. et al. (2021) Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 23(4), pp. 527-540. (doi: 10.1002/ejhf.2133) (PMID:33609068)

Tomasoni, D., Petrie, M. C. , Adamo, M. and Metra, M. (2021) Renin-angiotensin-aldosterone inhibitors and COVID-19: nearing the end of a media-fuelled controversy. European Journal of Heart Failure, 23(3), pp. 486-488. (doi: 10.1002/ejhf.2098) (PMID:33421242) (PMCID:PMC8013611)

Lee, M. M.Y. et al. (2021) Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. Open Heart, 8(1), e001453. (doi: 10.1136/openhrt-2020-001453) (PMID:33637568) (PMCID:PMC7919592)

Ehteshami-Afshar, S. et al. (2021) Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. Journal of the American Heart Association, 10(4), e019238. (doi: 10.1161/JAHA.120.019238) (PMID:33522249) (PMCID:PMC7955331)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)

Petrie, M. C. , Lee, M. M. and Lang, N. N. (2021) EMPEROR-REDUCED reigns while EMPERIAL whimpers. European Heart Journal, 42(6), pp. 711-714. (doi: 10.1093/eurheartj/ehaa965) (PMID:33367572)

Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)

Maznyczka, A. M. et al. (2021) Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. Heart, 107(4), pp. 299-312. (doi: 10.1136/heartjnl-2020-317828) (PMID:33436493)

Dobbin, S. J.H. , Petrie, M. C. , Myles, R. C. , Touyz, R. M. and Lang, N. N. (2021) Cardiotoxic effects of angiogenesis inhibitors. Clinical Science, 135(1), pp. 71-100. (doi: 10.1042/CS20200305) (PMID:33404052) (PMCID:PMC7812690)

Rossitto, G. et al. (2020) Reduced lymphatic reserve in heart failure with preserved ejection fraction. Journal of the American College of Cardiology, 76(24), pp. 2817-2829. (doi: 10.1016/j.jacc.2020.10.022) (PMID:33303070) (PMCID:PMC7724570)

Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)

Mackenzie, I. S. et al. (2020) Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet, 396(10264), pp. 1745-1757. (doi: 10.1016/S0140-6736(20)32234-0) (PMID:33181081)

Dewan, P. et al. (2020) The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE. European Journal of Heart Failure, 22(11), pp. 2123-2133. (doi: 10.1002/ejhf.1832) (PMID:32353205)

Ferreira, J. P. et al. (2020) Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 109(11), pp. 1358-1365. (doi: 10.1007/s00392-020-01632-x) (PMID:32215700)

McCartney, P. J. et al. (2020) Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. Efficacy and Mechanism Evaluation, 7(5), (doi: 10.3310/eme07050) (PMID:33175484)

McEwan, P., Darlington, O., McMurray, J. J.V. , Jhund, P. S. , Docherty, K. F. , Böhm, M., Petrie, M. C. , Bergenheim, K. and Qin, L. (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22(11), pp. 2147-2156. (doi: 10.1002/ejhf.1978) (PMID:32749733) (PMCID:PMC7756637)

Seferović, P. M. et al. (2020) Heart Failure Association of the European Society of Cardiology update on sodium glucose co‐transporter‐2 inhibitors in heart failure (an update on the Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology). European Journal of Heart Failure, 22(11), pp. 1984-1986. (doi: 10.1002/ejhf.2026) (PMID:33068051)

Lang, N. N. , Dobbin, S. J.H. and Petrie, M. C. (2020) Vericiguat in worsening heart failure – agonising over, or celebrating, agonism. Cardiovascular Research, 116(12), e152-e155. (doi: 10.1093/cvr/cvaa247) (PMID:32980877)

Butt, J. H. et al. (2020) Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort. European Journal of Heart Failure, 22(10), pp. 1777-1785. (doi: 10.1002/ejhf.1800) (PMID:32227556)

Seferović, P. M. et al. (2020) Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 22(9), pp. 1495-1503. (doi: 10.1002/ejhf.1954) (PMID:32618086)

Rossitto, G. et al. (2020) Tissue sodium excess is not hypertonic and reflects extracellular volume expansion. Nature Communications, 11, 4222. (doi: 10.1038/s41467-020-17820-2) (PMID:32839436) (PMCID:PMC7445299)

Bulluck, H. et al. (2020) Redefining adverse and reverse left ventricular remodeling by cardiovascular magnetic resonance following ST-segment elevation myocardial infarction and their implications on long-term prognosis. Circulation: Cardiovascular Imaging, 13(7), e009937. (doi: 10.1161/CIRCIMAGING.119.009937) (PMID:32689822)

Dobbin, S. J.H. et al. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22(7), pp. 1276-1277. (doi: 10.1002/ejhf.1847) (PMID:32379945)

Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)

Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)

Hawkins, N. M., Osmanska, J. and Petrie, M. C. (2020) Implantable cardioverter-defibrillators and survival - the fine line between efficacy concerns and ageism. European Journal of Heart Failure, 22(5), pp. 868-870. (doi: 10.1002/ejhf.1803) (PMID:32227573)

Hennigan, B. et al. (2020) Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial. Heart, 106(10), pp. 714-715. (doi: 10.1136/heartjnl-2019-316075) (PMID:32114516) (PMCID:PMC7229900)

Maznyczka, A. M. et al. (2020) Comparative significance of invasive measures of microvascular injury in acute myocardial infarction. Circulation: Cardiovascular Interventions, 13(5), e008505. (doi: 10.1161/CIRCINTERVENTIONS.119.008505) (PMID:32408817) (PMCID:PMC7237023)

Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)

Simpson, J. et al. (2020) Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish Heart Failure Registry to predict mortality and morbidity in chronic heart failure. JAMA Cardiology, 5(4), pp. 432-441. (doi: 10.1001/jamacardio.2019.5850) (PMID:31995119)

Docherty, K. F. et al. (2020) Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22(3), pp. 528-538. (doi: 10.1002/ejhf.1682) (PMID:31849164)

Lee, M. M.Y. , Petrie, M. C. , McMurray, J. J.V. and Sattar, N. (2020) How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? Arteriosclerosis, Thrombosis, and Vascular Biology, 40(3), pp. 506-522. (doi: 10.1161/atvbaha.119.311904) (PMID:31996025)

Serenelli, M. et al. (2020) Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(3), pp. 188-198. (doi: 10.1016/j.jchf.2019.09.011) (PMID:31926854) (PMCID:PMC7086149)

Ford, T. J. et al. (2020) Sex differences in procedural and clinical outcomes following rotational atherectomy. Catheterization and Cardiovascular Interventions, 95(2), pp. 232-241. (doi: 10.1002/ccd.28373) (PMID:31264314) (PMCID:PMC7027486)

Maznyczka, A. M. et al. (2020) One-year outcomes after low-dose intracoronary alteplase during primary percutaneous coronary intervention. The T-TIME randomized trial. Circulation: Cardiovascular Interventions, 13(2), e008855. (doi: 10.1161/CIRCINTERVENTIONS.119.008855) (PMID:32069113)

Seferović, P. M. et al. (2020) European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure. European Journal of Heart Failure, 22(2), pp. 196-213. (doi: 10.1002/ejhf.1673) (PMID:31816162)

Kosiborod, M. N. et al. (2020) Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138) (PMID:31736335) (PMCID:PMC6964869)

Martinez, F. A. et al. (2020) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation, 141(2), pp. 100-111. (doi: 10.1161/CIRCULATIONAHA.119.044133) (PMID:31736328)

Dewan, P. et al. (2019) Sex-related differences in heart failure with preserved ejection fraction. Circulation: Heart Failure, 12(12), e006539. (doi: 10.1161/CIRCHEARTFAILURE.119.006539) (PMID:31813280)

McMurray, J. J.V. et al. (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)

Stirrat, C. G. et al. (2019) Ferumoxytol-enhanced MRI in patients with prior cardiac transplantation. Open Heart, 6(2), e001115. (doi: 10.1136/openhrt-2019-001115) (PMID:31673393) (PMCID:PMC6802993)

Anker, S. D. et al. (2019) Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial. European Journal of Heart Failure, 21(10), pp. 1279-1287. (doi: 10.1002/ejhf.1596) (PMID:31523904)

Howlett, J. G. et al. (2019) CABG improves outcomes in patients with ischemic cardiomyopathy 10-year follow-up of the STICH trial. JACC: Heart Failure, 7(10), pp. 878-887. (doi: 10.1016/j.jchf.2019.04.018) (PMID:31521682)

Packer, M. et al. (2019) Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial. European Journal of Heart Failure, 21(10), pp. 1270-1278. (doi: 10.1002/ejhf.1536) (PMID:31584231)

Nicolau, J. C. et al. (2019) Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trial. International Journal of Cardiology, 291, pp. 36-41. (doi: 10.1016/j.ijcard.2019.03.029) (PMID:30929973)

Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)

Lee, M. M.Y. et al. (2019) Invasive versus medical management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: a pilot randomized controlled trial. Circulation: Cardiovascular Interventions, 12(8), e007830. (doi: 10.1161/CIRCINTERVENTIONS.119.007830) (PMID:31362541)

Rørth, R., Dewan, P. , Kristensen, S. L., Jhund, P. S. , Petrie, M. C. , Køber, L. and McMurray, J. J.V. (2019) Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clinical Research in Cardiology, 108(8), pp. 868-877. (doi: 10.1007/s00392-019-01415-z) (PMID:30689020) (PMCID:PMC6652172)

Shen, L. et al. (2019) Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 21(8), pp. 974-984. (doi: 10.1002/ejhf.1535) (PMID:31271255) (PMCID:PMC7079555)

Bauersachs, J. et al. (2019) Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 21(7), pp. 827-843. (doi: 10.1002/ejhf.1493) (PMID:31243866)

Cleland, J. G.F. , Hindricks, G. and Petrie, M. (2019) The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization. European Heart Journal, 40(26), pp. 2128-2130. (doi: 10.1093/eurheartj/ehz409) (PMID:31257403)

Ahmad, F. A., Petrie, M. C. , McMurray, J. J.V. and Lang, N. N. (2019) Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. European Journal of Heart Failure, 21(6), pp. 699-702. (doi: 10.1002/ejhf.1463) (PMID:30972879) (PMCID:PMC6618029)

Clark, A. L., Kalra, P. R., Petrie, M. C. , Mark, P. B. , Tomlinson, L. A. and Tomson, C. R.V. (2019) Change in renal function associated with drug treatment in heart failure: national guidance. Heart, 105(12), pp. 904-910. (doi: 10.1136/heartjnl-2018-314158) (PMID:31118203) (PMCID:PMC6582720)

Haig, C. et al. (2019) Current smoking and prognosis after acute ST-segment elevation myocardial infarction: new pathophysiological insights. JACC: Cardiovascular Imaging, 12(6), pp. 993-1003. (doi: 10.1016/j.jcmg.2018.05.022) (PMID:30031700) (PMCID:PMC6547246)

Dewan, P. et al. (2019) Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 21(5), pp. 577-587. (doi: 10.1002/ejhf.1347) (PMID:30536678) (PMCID:PMC6607486)

McMurray, J. J.V. et al. (2019) A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). European Journal of Heart Failure, 21(5), pp. 665-675. (doi: 10.1002/ejhf.1432) (PMID:30895697) (PMCID:PMC6607736)

Shen, L. et al. (2019) Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7(5), pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006) (PMID:30981744)

Maznyczka, A. M. et al. (2019) Sex-based associations with microvascular injury and outcomes after ST-segment elevation myocardial infarction. Open Heart, 6(1), e000979. (doi: 10.1136/openhrt-2018-000979) (PMID:31168381) (PMCID:PMC6519583)

Pettit, S. J. and Petrie, M. C. (2019) Transplantation of hearts donated after circulatory-determined death: a song of fire and ice. Circulation: Heart Failure, 12(4), e005991. (doi: 10.1161/CIRCHEARTFAILURE.119.005991) (PMID:30998399)

Wolsk, E. et al. (2019) Central and peripheral determinants of exercise capacity in heart failure patients with preserved ejection fraction. JACC: Heart Failure, 7(4), pp. 321-332. (doi: 10.1016/j.jchf.2019.01.006) (PMID:30852235)

Januzzi, J. et al. (2019) Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 21(3), pp. 386-388. (doi: 10.1002/ejhf.1419) (PMID:30767353)

Loader, J. et al. (2019) Prevalence and profile of "seasonal frequent flyers" with chronic heart disease: analysis of 1598 patients and 4588 patient-years follow-up. International Journal of Cardiology, 279, pp. 126-132. (doi: 10.1016/j.ijcard.2018.12.060) (PMID:30638747)

Mamet, H., Petrie, M. C. and Rocchiccioli, P. (2019) Type 1 diabetes mellitus and coronary revascularization. Cardiovascular Endocrinology and Metabolism, 8(1), pp. 35-38. (doi: 10.1097/XCE.0000000000000166) (PMID:31646296) (PMCID:PMC6739890)

Mangion, K. et al. (2019) Predictors of segmental myocardial functional recovery in patients after an acute ST-elevation myocardial infarction. European Journal of Radiology, 112, pp. 121-129. (doi: 10.1016/j.ejrad.2019.01.010) (PMID:30777200) (PMCID:PMC6390173)

Avtaar Singh, S. S. et al. (2019) Mechanical circulatory support for refractory cardiogenic shock post-acute myocardial infarction-a decade of lessons. Journal of Thoracic Disease, 11(2), pp. 542-548. (doi: 10.21037/jtd.2019.01.21) (PMID:30962998) (PMCID:PMC6409252)

Kaye, D. M. et al. (2019) Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Failure, 6(1), pp. 62-69. (doi: 10.1002/ehf2.12350) (PMID:30311437) (PMCID:PMC6351895)

Mangion, K. et al. (2019) Circumferential strain predicts major adverse cardiovascular events following an acute ST-segment-elevation myocardial infarction. Radiology, 290(2), pp. 329-337. (doi: 10.1148/radiol.2018181253) (PMID:30457480)

Dewan, P. et al. (2019) Differential impact of heart failure with reduced ejection fraction on men and women. Journal of the American College of Cardiology, 73(1), pp. 29-40. (doi: 10.1016/j.jacc.2018.09.081) (PMID:30621948)

McCartney, P. J. et al. (2019) Effect of low-dose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction: a randomized clinical trial. JAMA: Journal of the American Medical Association, 321(1), pp. 56-68. (doi: 10.1001/jama.2018.19802) (PMID:30620371) (PMCID:PMC6583564)

Lee, M. M. Y. , McMurray, J. J.V. , Lorenzo-Almorós, A., Kristensen, S. L., Sattar, N. , Jhund, P. S. and Petrie, M. C. (2019) Diabetic cardiomyopathy. Heart, 105(4), pp. 337-345. (doi: 10.1136/heartjnl-2016-310342) (PMID:30337334)